<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004787.pub2" GROUP_ID="LIVER" ID="309704022521554386" MERGED_FROM="" MODIFIED="2012-06-08 15:33:01 +0200" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2012-06-08 15:33:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2008-09-01 20:05:16 +0200" MODIFIED_BY="Roberto S Oliveri">Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma</TITLE>
<CONTACT>
<PERSON ID="17036" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Oliveri</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION/>
<EMAIL_1>mafioso_dk@yahoo.dk</EMAIL_1>
<EMAIL_2>oliveri@rh.dk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oncology</DEPARTMENT>
<ORGANISATION>The Finsen Centre, section 5073, Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+44 3545 4676</PHONE_1>
<PHONE_2>+44 3545 5823</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-06-08 13:24:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="17036" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Oliveri</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION/>
<EMAIL_1>mafioso_dk@yahoo.dk</EMAIL_1>
<EMAIL_2>oliveri@rh.dk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oncology</DEPARTMENT>
<ORGANISATION>The Finsen Centre, section 5073, Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+44 3545 4676</PHONE_1>
<PHONE_2>+44 3545 5823</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6564" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Jørn</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wetterslev</LAST_NAME>
<SUFFIX>MD, Ph. D.</SUFFIX>
<POSITION>Chief Physician</POSITION>
<EMAIL_1>wetterslev@ctu.rh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7159</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7001</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6439" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D, Dr. Med. Sci.</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>cgluud@ctu.rh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+ 45 3545 7175</PHONE_1>
<PHONE_2/>
<FAX_1>+ 45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-03-10 13:59:28 +0100" MODIFIED_BY="Sarah Louise Klingenberg">
<UP_TO_DATE>
<DATE DAY="16" MONTH="2" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="9" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="1" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2012-06-08 15:33:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-06-08 15:33:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="8" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Replies to comments (by Marshall Hicks and Mike Wallace from The Society of Interventional Radiology, USA) are provided by the review authors. See the <I>Feedback</I> section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-05-16 11:09:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="16" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Comment sent by Marshall Hicks and Mike Wallace from The Society of Interventional Radiology, USA. Reply from the review authors is to be submitted in June 2012.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-10-08 19:12:58 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-09-25 18:53:13 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-09-25 18:53:13 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-09-25 18:53:13 +0200" MODIFIED_BY="[Empty name]">
<NAME>The Copenhagen Trial Unit, Rigshospitalet, Copenhagen University Hospital</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-05-16 11:14:10 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-05-16 11:14:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2012-05-16 11:14:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma</TITLE>
<SUMMARY_BODY MODIFIED="2012-05-16 11:14:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of death from cancer. Several interventions have been tried in order to prolong survival and improve quality of life for such patients. During the last 20 years, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) have gained considerable attention and have been advocated as standard loco-regional treatment for unresectable HCC. The review included nine trials with 645 participants. Six trials assessed TACE versus control and three trials assessed TAE versus control. All trials had risks of systematic errors ('bias'). Contrary to current practice in many hospitals, we could not demonstrate any beneficial effect of TACE or TAE on either survival or tumour growth in patients with primary liver cancer not suitable for surgical resection. Furthermore, we calculated that more clinical trials involving a further 383 trial participants may be needed before firm evidence may become available. Importantly, TACE or TAE is associated with a wide range of adverse events, some being potentially serious. Accordingly, we recommend that TACE or TAE should not be used as standard treatment for liver cancer until firmer evidence is available from randomised clinical trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-05-16 11:14:10 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-03-12 13:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatocellular carcinoma (HCC) results in more than 600,000 deaths per year. Transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) have become standard loco-regional treatments for unresectable HCC.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-03-12 13:33:07 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of TACE or TAE.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-03-10 13:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, <I>The Cochrane Cancer Network Register</I>, <I>The Cochrane Central Register of Controlled Trials (CENTRAL)</I> in<I> The Cochrane Library, MEDLINE</I>, <I>EMBASE</I>, <I>Science Citation Index Expanded</I>, and <I>The Latin American Caribbean Health Sciences Literature</I> (<I>LILACS</I>) from dates of inceptions up to September 2010.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-10-04 11:40:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We considered for inclusion all randomised trials that compared TACE or TAE versus placebo, sham, or no intervention. Co-interventions were allowed if comparable between intervention groups. Trials with inadequate randomisation were excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-10-01 18:04:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>For all-cause mortality, we calculated the log hazard ratio (HR) with standard error as point estimate and pooled them for meta-analysis using the inverse variance method. Sub-group analyses were performed regarding intervention regimen, trial truncation, or co-interventions. We validated the results with trial sequential analyses. We used random-effects model in all meta-analyses in anticipation of statistical heterogeneity among the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-16 20:48:52 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included nine trials with 645 participants. Six trials assessed TACE versus control and three trials assessed TAE versus control. Seven trials had low risk of selection bias based on adequate generation of allocation sequence and concealment - but all these trials had other risks of bias. Three trials were stopped early due to interim inspections and one due to slow accrual. For all-cause mortality, statistical heterogeneity between trials was low to moderate (I<SUP>2</SUP>= 30%). Meta-analysis of trials with low risk of selection bias showed that TACE or TAE versus control does not significantly increase survival (HR 0.88; 95% CI 0.71 to 1.10). Two trials with low risk of selection bias, no early stopping, and no co-intervention did not establish any significant effect of TACE or TAE on overall survival (hazard ratio 1.22, 95% confidence interval 0.82 to 1.83; P = 0.33). Trial sequential analysis confirmed the absence of evidence for a beneficial effect of TACE or TAE on survival indicating the need for future randomisation of up to 383 additional participants. Substantial differences in criteria for assessing tumour response did not allow quantitative analyses. One trial investigated quality of life but did not detect any significant differences between the intervention groups. A range of adverse events including post-embolisation syndrome and serious complications were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-05-16 11:14:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>There is no firm evidence to support or refute TACE or TAE for patients with unresectable HCC. More adequately powered and bias-protected trials are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-05-16 10:59:52 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of death from cancer, resulting in more than 600,000 deaths per year (<LINK REF="REF-El_x002d_Serag-2007" TYPE="REFERENCE">El-Serag 2007</LINK>). It has a high incidence in Southeast Asia and sub-Saharan Africa where it is mainly associated with hepatitis B (<LINK REF="REF-Bosch-2004" TYPE="REFERENCE">Bosch 2004</LINK>). However, incidences have begun to rise in developed countries traditionally regarded as low or intermediate areas (<LINK REF="REF-El_x002d_Serag-1999" TYPE="REFERENCE">El-Serag 1999</LINK>; <LINK REF="REF-McGlynn-2001" TYPE="REFERENCE">McGlynn 2001</LINK>), and HCC has disproportionately affected age groups that were not typically affected in the past (<LINK REF="REF-El_x002d_Serag-2003" TYPE="REFERENCE">El-Serag 2003</LINK>). The increase observed in the Western countries is mainly caused by rising incidence of cirrhosis with especially hepatitis C being a significant contributor (<LINK REF="REF-Davila-2004" TYPE="REFERENCE">Davila 2004</LINK>), and HCC has become the main cause of death among cirrhotic persons (<LINK REF="REF-Sangiovanni-2004" TYPE="REFERENCE">Sangiovanni 2004</LINK>). Early diagnosis of HCC is rare, and most persons present with locally advanced or metastatic disease. Prognosis is further complicated by the underlying liver function, which in turn affects the applicability of treatments (<LINK REF="REF-Llovet-2003a" TYPE="REFERENCE">Llovet 2003a</LINK>). Accordingly, only 10% to 30% of newly diagnosed HCC persons are eligible for radical treatment such as resection, liver transplantation, and percutaneous ablation techniques (ethanol injection, radiofrequency ablation) (<LINK REF="REF-Chlebowski-1984" TYPE="REFERENCE">Chlebowski 1984</LINK>; <LINK REF="REF-Nagorney-1989" TYPE="REFERENCE">Nagorney 1989</LINK>; <LINK REF="REF-Choi-1990" TYPE="REFERENCE">Choi 1990</LINK>; <LINK REF="REF-Paquet-1991" TYPE="REFERENCE">Paquet 1991</LINK>). </P>
<P>Transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) have gained considerable attention and have been advocated as standard loco-regional life-extending treatment for unresectable HCC. The interventions exploit the fact that the highly vascularised tumours are supplied by the hepatic arteries, whereas the non-neoplastic liver parenchyma has dual blood supply. The tumour-providing branches of the hepatic arteries are intubated and the application of an embolizing agent results in ischaemia of the tumour (TAE). This intervention may now potentially be enhanced in TACE by the addition of an emulsified chemotherapeutic agent to TAE.</P>
<P>The implementation of TACE has primarily been based on reported large beneficial effects on survival from in two clinical trials (<LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>; <LINK REF="STD-Lo-2002" TYPE="STUDY">Lo 2002</LINK>) and one sub-sequent meta-analysis (<LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>). However, number of events remains low and meta-analytic methodology has undergone developments, including assessment of risk of bias in the trials based on separate domains (<LINK REF="REF-Higgins-2009a" TYPE="REFERENCE">Higgins 2009a</LINK>), risks associated with early stopping of trials (<LINK REF="REF-Montori-2005" TYPE="REFERENCE">Montori 2005</LINK>; <LINK REF="REF-Bassler-2008" TYPE="REFERENCE">Bassler 2008</LINK>), and trial sequential analysis (TSA) (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-11-04 13:09:38 +0100" MODIFIED_BY="[Empty name]">
<P>The primary objective of this review was to conduct a systematic review of randomised clinical trials assessing the beneficial and harmful effect of TACE or TAE in patients with unresectable HCC, using the most rigorous methodology and most recent trial data available in accordance with the latest Cochrane Collaboration guidelines (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). </P>
</OBJECTIVES>
<METHODS MODIFIED="2012-05-16 10:59:52 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2008-09-29 12:30:27 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trials irrespective of language, publication status, or date were considered for inclusion. Trials with clear inadequate generation of allocation sequence (eg, allocation by date of birth, day of the week etc.) or inadequate allocation concealment were not included.<BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-10-01 18:11:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Participants diagnosed with HCC according to the definitions of the individual trials. Trials with no explicit definitions were also included. Participants were categorised as having:<BR/>
</P>
<OL>
<LI>Established HCC: present by histology or cytology.</LI>
<LI>Likely HCC: presence based on nonpathologic para-clinical diagnosis (typical radiological imaging that could include ultrasound, computed tomography, magnetic resonance imaging, or angiogram plus raised alfa-foetoprotein more than 500 ng/ml with history of chronic liver disease).</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-09-29 12:32:22 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>We assessed TACE or TAE versus placebo or sham, or no treatment. Furthermore, TACE or TAE could be employed either alone or as an adjunct to other co-interventions as long as they were similar in both arms of the trial.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>All-cause mortality.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Tumour response.</LI>
<LI>Quality of life according to the measures used in the individual trials.</LI>
<LI>Adverse events (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</LI>
<LI>Duration of hospital stay</LI>
<LI>Cost-effectiveness.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-03-11 13:01:00 +0100" MODIFIED_BY="[Empty name]">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>), <I>The Cochrane Cancer Network register</I>, <I>The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE</I>, <I>EMBASE</I>, <I>Science Citation Index Expanded</I>, and <I>The Latin American Caribbean Health Sciences Literature</I> (<I>LILACS</I>) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>) according to the search strategies and time spans given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-05-16 10:59:52 +0200" MODIFIED_BY="[Empty name]">
<P>Meta-analyses were conducted according to the recommendations in <I>The</I> <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) and <I>The Cochrane Hepato-Biliary Group Module </I>(<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>) using the software package Review Manager 5 (<A HREF="http://archie.cochrane.org/sections/documents/view?document=3340BBE982E26AA2007919019AEEF063&amp;format=REVMAN#REF-RevMan-2008">RevMan 2008</A>). Identified trials were listed, and RSO and CG evaluated whether the trials fulfilled the inclusion criteria. Excluded trials were listed with reasons for exclusion. Data were extracted by RSO and validated by JW and CG. Disagreements were resolved by discussion.<B>
<BR/>
</B>
</P>
<DATA_EXTRACTION MODIFIED="2011-02-16 20:47:41 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We extracted general information (title, investigators, source, contact address, country, publication status, language, year of publication, and sponsoring of trial), trial characteristics (design, sample size, duration/follow-up, and quality assessment criteria), participant-related data (diagnostic criteria, eligibility criteria, exclusion criteria, baseline characteristics, number of persons allocated to each group, numbers at risk), intervention scheme (drug, dose, and route for experimental and control interventions), and time-to-event summary data, and statistics (hazard ratio (HR) with 95% confidence interval (CI), log-rank P-value, or log-rank &#967;<SUP>2 </SUP>value, and number of events). If essential data were missing in a published trial, we contacted the principal investigators for further details.</P>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>For meta-analyses, the natural logarithm (ln) of the HR and its standard error (SE) were calculated either directly or indirectly from relevant summary statistics (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>; <LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>), whether reported or provided on our request. For direct calculations we used the crude univariate HR, since corrected values estimated by a regression modelling technique are at risk of over estimating treatment effects (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>). When a trial involved two experimental groups, both of which were going into the same meta-analytic estimation, the ln(HR) for each experimental group versus control was left intact, but the corresponding SE(ln(HR)) was multiplied by &#8730;2, thereby producing two half-weight contributions to the overall effect estimation (D.G. Altman and J. Hilden, personal communications). All values of ln(HR) and SE(ln(HR)) were calculated using a specifically developed Excel spreadsheet (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). All meta-analyses were performed with Review Manager 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</P>
<P>The overall pooled HR and 95% confidence interval (CI) were calculated with the inverse variance method (<LINK REF="REF-Deeks-2009" TYPE="REFERENCE">Deeks 2009</LINK>). We used the random-effects model in anticipation of clinical and methodological diversity between trials (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
<P>For trial sequential analysis the required number of participants ('information size') for a meta-analysis should be at least as large as the sample size needed in a single trial with adequate power (<LINK REF="REF-Pogue-1998" TYPE="REFERENCE">Pogue 1998</LINK>; <LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). We calculated the required information size based on a mortality of 80% in the control group, a relative risk reduction (RRR) of 10%, an alpha of 5%, a beta of 20%, and the estimated diversity (D) in the meta-analysis (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). To adjust for between-trial heterogeneity, the required information size was corrected with the factor 1/(1-D<SUP>2</SUP>) to yield the heterogeneity-adjusted information size (LBHIS) (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). Cumulative Z-curves were constructed after including each trial according to the order of their publication year. We assessed the crossing of the cumulative Z-curves of the naive two-sided boundary of 1.96 (nominal alpha = 0.05; beta = 20%) and discrete trial sequential monitoring boundary (TSMB) using the calculated LBHIS. All calculations were performed with Copenhagen Trial Unit's TSA version 8.03 software (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).</P>
<P>Sub-group analyses were performed with stratification according to risk of bias, TAE or TACE, TAE or TACE and low risk of selection bias, trial truncation, co-intervention, low risk of selection bias, and median survival in the control group. Differences in treatment effects between subgroups were evaluated with the test of interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>).</P>
<P>For all calculations a two-tailed P value of less than 0.05 was considered statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tumour response</HEADING>
<P>In case of uniform assessments of tumour response, we planned to calculate the risk ratio from the proportion of participants reported as having experienced partial or complete response ('responders').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>We planned to use the reported means with standard deviation (SD) for the calculation of the mean difference.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-05-16 10:59:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We classified trials with adequate randomisation procedure (ie, sequence generation plus allocation concealment) as trials with low risk of selection bias (<LINK REF="REF-Higgins-2009a" TYPE="REFERENCE">Higgins 2009a</LINK>). Adequate sequence generation and allocation concealment reduces the risk of selection bias, whereas unclear or inadequate randomisation is associated with a risk of biased overestimation of treatment effects (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). Accordingly, trials with unclear randomisation were classified as trials with high risk of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). We also assessed other components of bias risk according to the <I>Cochrane Handbook for Systematic Reviews of Intervention </I>(<LINK REF="REF-Higgins-2009a" TYPE="REFERENCE">Higgins 2009a</LINK>) and <I>The Cochrane Hepato-Biliary Group Module </I>(<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>):</P>
<P>
<I>Allocation sequence generation</I> <BR/>- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards and throwing dice are adequate if performed by an independent adjudicator.<BR/>- Uncertain risk of bias: the trial is described as randomised, but the method of sequence generation was not specified.<BR/>- High risk of bias: the sequence generation method is not, or may not be, random. Quasi-randomised studies, those using dates, names, or admittance numbers in order to allocate patients are inadequate and will be excluded for the assessment of benefits but not for harms.<BR/>
<BR/>
<I>Allocation concealment</I>
<BR/>- Low risk of bias: allocation was controlled by a central and independent randomisation unit, sequentially numbered, opaque and sealed envelopes or similar, so that intervention allocations could not have been foreseen in advance of, or during, enrolment.<BR/>- Uncertain risk of bias: the trial was described as randomised but the method used to conceal the allocation was not described, so that intervention allocations may have been foreseen in advance of, or during, enrolment.<BR/>- High risk of bias: if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised. Quasi-randomised studies will be excluded for the assessment of benefits but not for harms.<BR/>
<BR/>
<I>Blinding</I>
<BR/>- Low risk of bias: the trial was described as blinded, the parties that were blinded, and the method of blinding was described, so that knowledge of allocation was adequately prevented during the trial.<BR/>- Uncertain risk of bias: the trial was described as blind, but the method of blinding was not described, so that knowledge of allocation was possible during the trial.<BR/>- High risk of bias, the trial was not blinded, so that the allocation was known during the trial.<BR/>
<BR/>
<I>Incomplete outcome data</I>
<BR/>- Low risk of bias: the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.<BR/>- Uncertain risk of bias: the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.<BR/>- High risk of bias: the number or reasons for dropouts and withdrawals were not described.<BR/>
<BR/>
<I>Selective outcome reporting</I>
<BR/>- Low risk of bias: pre-defined, or clinically relevant and reasonably expected outcomes are reported on.<BR/>- Uncertain risk of bias: not all pre-defined, or clinically relevant and reasonably expected outcomes are reported on or are not reported fully, or it is unclear whether data on these outcomes were recorded or not.<BR/>- High risk of bias: one or more clinically relevant and reasonably expected outcomes were not reported on; data on these outcomes were likely to have been recorded.<BR/>
</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-02-26 12:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>Statistical heterogeneity between trials was measured by the I<SUP>2</SUP> statistic, which describes the proportion of heterogeneity not ascribed to random error (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). Subgroup analyses were performed according to intervention scheme (TAE or TACE), trial truncation (early stopping), co-intervention, and trial truncation plus co-intervention.</P>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Publication bias</I>
</HEADING>
<P>Publication bias was assessed by visual inspection of a funnel plot (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-02-16 20:48:32 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2010-11-07 14:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>After performing a sensitive literature search in relevant electronic databases (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), we retrieved 1701 references (including doublets). After screening titles, we excluded 1161 references of clear irrelevance. We examined 40 references in further detail (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We ended up identifying 13 trials (reported in 13 references) eligible for inclusion: <LINK REF="STD-Pelletier-1990" TYPE="STUDY">Pelletier 1990</LINK>; <LINK REF="STD-GETCH-1995" TYPE="STUDY">GETCH 1995</LINK>; <LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>; <LINK REF="STD-Bruix-1998" TYPE="STUDY">Bruix 1998</LINK>; <LINK REF="STD-Pelletier-1998" TYPE="STUDY">Pelletier 1998</LINK>; <LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>; <LINK REF="STD-Llovet-_x005b_TAE_x005d_-2002" TYPE="STUDY">Llovet [TAE] 2002</LINK>; <LINK REF="STD-Lo-2002" TYPE="STUDY">Lo 2002</LINK>; <LINK REF="STD-Xiao-2003" TYPE="STUDY">Xiao 2003</LINK>; <LINK REF="STD-Akamatsu-2004" TYPE="STUDY">Akamatsu 2004</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>; and <LINK REF="STD-Doffo_x00eb_l-2008" TYPE="STUDY">Doffoël 2008</LINK>. However, two trials did not report the primary outcome (all-cause mortality) or any secondary outcomes (<LINK REF="STD-Xiao-2003" TYPE="STUDY">Xiao 2003</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>), and one trial did not provide data adequate for hazard ratio meta-analysis of survival (<LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>). We were unable to obtain further information from the authors. Furthermore, one trial (<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>) was excluded due to a later retraction of the trial based on "concerns about the integrity of the<SUP> </SUP>data and the veracity of the report" (<LINK REF="REF-DeAngelis-2009" TYPE="REFERENCE">DeAngelis 2009</LINK>).</P>
<P>The nine trials with quantitative data for survival analysis comprised a total of 645 participants (range 42 to 123 participants) of European, Asian, or North American origin. Three trials investigated TAE and six investigated TACE. Three trials had comparable co-intervention in both the experimental and control group: one with radiofrequency ablation or percutaneous ethanol injection (<LINK REF="STD-Akamatsu-2004" TYPE="STUDY">Akamatsu 2004</LINK>) and two with tamoxifen (<LINK REF="STD-Pelletier-1998" TYPE="STUDY">Pelletier 1998</LINK>; <LINK REF="STD-Doffo_x00eb_l-2008" TYPE="STUDY">Doffoël 2008</LINK>). Three trials had surgical resections as co-intervention (<LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>; <LINK REF="STD-Xiao-2003" TYPE="STUDY">Xiao 2003</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>) but could not provide data for the meta-analyses as stated above.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-07 14:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>After the provision of additional information from the responsible investigators, we ended up with seven trials having both adequate sequence generation and adequate allocation concealment. Accordingly, these seven trials were classified as trials with low risk of selection bias (<LINK REF="STD-Pelletier-1990" TYPE="STUDY">Pelletier 1990</LINK>; <LINK REF="STD-GETCH-1995" TYPE="STUDY">GETCH 1995</LINK>; <LINK REF="STD-Bruix-1998" TYPE="STUDY">Bruix 1998</LINK>; <LINK REF="STD-Pelletier-1998" TYPE="STUDY">Pelletier 1998</LINK>; <LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>; <LINK REF="STD-Llovet-_x005b_TAE_x005d_-2002" TYPE="STUDY">Llovet [TAE] 2002</LINK>; <LINK REF="STD-Doffo_x00eb_l-2008" TYPE="STUDY">Doffoël 2008</LINK>) and two as having high risk of selection bias (<LINK REF="STD-Lo-2002" TYPE="STUDY">Lo 2002</LINK>; <LINK REF="STD-Akamatsu-2004" TYPE="STUDY">Akamatsu 2004</LINK>).</P>
<P>Three trials were stopped early due to repeated interim inspections using triangular test with discrete monitoring as stopping boundaries (<LINK REF="STD-GETCH-1995" TYPE="STUDY">GETCH 1995</LINK>; <LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>; <LINK REF="STD-Llovet-_x005b_TAE_x005d_-2002" TYPE="STUDY">Llovet [TAE] 2002</LINK>). One trial was stopped due to lack of treatment benefit (crossing the lower triangular border at the fifth interim inspection) (<LINK REF="STD-GETCH-1995" TYPE="STUDY">GETCH 1995</LINK>). One trial was stopped for treatment benefit (crossing the upper triangular border at the ninth interim inspection) (<LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>). One trial was stopped prematurely while data were still accumulating within the triangular borders ('under-running') thus being unable to either accept or reject the null hypothesis (<LINK REF="STD-Llovet-_x005b_TAE_x005d_-2002" TYPE="STUDY">Llovet [TAE] 2002</LINK>).</P>
<P>No trial was blinded with regard to participant or care giver due to the nature of the intervention. Regarding tumour response, one trial explicitly reported that the data assessors (eg, radiologists) were blinded.</P>
<P>All trials were reported according to the intention-to-treat principle. We did not detect any signs of selective reporting, although some trials indicated vested interest bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-02-16 20:48:32 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">All-cause mortality</HEADING>
<P>A funnel plot did not indicate bias. Heterogeneity between all nine trials was low to moderate (I<SUP>2 </SUP>= 30%). Pooling of HRs from seven trials with low risk of bias showed no significant effect of TACE or TAE on survival (overall HR 0.88; 95% CI 0.71 to 1.10; P = 0.27). By contrast, the two trials with high risk of bias showed significant effect (HR 0.53; 95% CI 0.34 to 0.83; P = 0.005) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The difference in HR between the two subgroups of trials stratified according to risk of bias was significant (test of interaction P = 0.046). Overall meta-analysis of all nine trials yielded no significant intervention effect (HR 0.81; 95% CI 0.64 to 1.02; P = 0.07).</P>
<P>Based upon an estimated mortality of 80% in the control group, a relative risk reduction of 10% in the TACE or TAE group, an alpha of 5%, a beta of 20%, and diversity estimated to 13% in all trials in a random-effects model meta-analyses of relative risk we calculated that the required information size to detect or reject such an intervention effect as 1028 patients (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). To this date, only 645 participants have been randomised and the cumulative Z-score did not cross any trial sequential monitoring boundaries. Accordingly, we have only obtained about two thirds of the required information size to detect (or reject) a 10% relative risk reduction of mortality.</P>
<P>A subgroup analysis stratified according to TACE or TAE showed no significant effect versus control (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Exclusion of the two trials with high risk of selection bias (<LINK REF="STD-Lo-2002" TYPE="STUDY">Lo 2002</LINK>; <LINK REF="STD-Akamatsu-2004" TYPE="STUDY">Akamatsu 2004</LINK>) just reduced the estimate of the intervention effect and widened the confidence interval further (Figure 8).</P>
<P>When trials where stratified according to early stopping, the truncated trials showed significant intervention effect of TACE and TAE, whereas the non-truncated trials showed no significant intervention effect (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The difference in HR between the two sub-groups of trials was insignificant (test of interaction P =<B> </B>0.38).</P>
<P>When trials where stratified according to the presence or absence of co-intervention, there was no significant intervention effect in both sub-groups (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>A subgroup analysis stratified according to trial truncation plus co-intervention showed insignificant effect in the non-truncated trials without co-intervention (data not shown). When trials with high risk of selection bias were excluded from the analysis, the meta-analysis of the two remaining non-truncated trials with low risk of selection bias and without co-interventions (<LINK REF="STD-Pelletier-1990" TYPE="STUDY">Pelletier 1990</LINK>; <LINK REF="STD-Bruix-1998" TYPE="STUDY">Bruix 1998</LINK>) resulted in a HR of 1.22 (95% CI 0.82 to 1.83) whereas the truncated trials with co-interventions showed a HR of 0.7)9 (95% CI 0.63 to 1.00) (Figure 10). The difference in HR between these two sub-groups of trials with low risk of bias was insignificant (test of interaction P = 0.07).</P>
<P>A further subgroup analysis stratified the trials according to the 50% survival in the control groups was performed as a post-hoc analysis. The 50% survival in the control groups were estimated from the published survival curves by visual extrapolation if needed. The median cut-off value was 12 months. We were unable to include one trial in this subgroup analysis due to lack of a survival curve (<LINK REF="STD-Llovet-_x005b_TAE_x005d_-2002" TYPE="STUDY">Llovet [TAE] 2002</LINK>). Both subgroups yielded no significant effect of TAE or TACE (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) and there was no difference in HR between the two subgroups (test of interaction P = 0.68).</P>
<P>One trial using partial hepatectomy as co-intervention (<LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>) did not report overall survival for all participants combined (N = 140). Instead, data were reported as survival percentages for two subgroups (radical and palliative resections, respectively). The study reported a survival advantage of TACE plus partial hepatectomy versus partial hepatectomy alone, which was significant in both sub-groups (radical resection: P = 0.0014; palliative resection: P = 0.0024). Due to the nature of the data, figures were not suitable for meta-analysis of hazard ratios (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tumour response</HEADING>
<P>Seven trials reported evaluation of tumour response. However, criteria regarding response evaluation and effect measures varied substantially between trials (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>No trial used the RECIST (Response Evaluation Criteria In Solid Tumours) guidelines (<LINK REF="REF-Therasse-2000" TYPE="REFERENCE">Therasse 2000</LINK>; <LINK REF="REF-Eisenhauer-2009" TYPE="REFERENCE">Eisenhauer 2009</LINK>) nor the guidelines for evaluation of tumour response in HCC developed by the European Association for the Study of the Liver (EASL) (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>). Accordingly, meta-analysis was not considered possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>One trial provided details on quality of life (Spitzer index), but did not detect any significant difference between the two groups (<LINK REF="STD-Doffo_x00eb_l-2008" TYPE="STUDY">Doffoël 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Descriptions of adverse events were of anecdotal nature and did not allow meta-analytic calculations. Post-embolisation syndrome consisting of transient fever, abdominal pain, and elevated transaminases was frequently reported among participants undergoing TAE or TACE (about 80%). In addition, a number of severe, albeit rare, adverse events were reported including acute renal failure, acute gastroduodenal ulcerations, ascites, encephalopathy, transient liver failure, cholecystitis, bacteraemia, and bleeding from femoral puncture site.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Duration of hospital stay and cost-effectiveness</HEADING>
<P>No trial reported data on duration of hospital stay or cost-effectiveness.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-02-16 20:27:40 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Contrary to current clinical practice, we conclude that there is absence of evidence of TACE or TAE having a beneficial effect on survival in participants with unresectable HCC. Methods of tumour response evaluation and reporting of adverse events varied considerably and did not allow meta-analysis of data. Only one trial assessed quality of life systematically, but did not observe an effect of the experimental intervention. No trial reported data on duration of hospital stay or cost-effectiveness.</P>
<P>Our systematic review poses a number of methodological advantages compared to previous meta-analyses of the effects of TAE or TACE (<LINK REF="REF-Camm_x00e0_-2002" TYPE="REFERENCE">Cammà 2002</LINK>; <LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>).</P>
<P>First, two additional eligible trials have been published (<LINK REF="STD-Akamatsu-2004" TYPE="STUDY">Akamatsu 2004</LINK>; <LINK REF="STD-Doffo_x00eb_l-2008" TYPE="STUDY">Doffoël 2008</LINK>). We have also included in the review previously unidentified trials (albeit the data were not reported in adequate-enough detail to allow us to enter them into the quantitative analyses of the primary outcome ) (<LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>; <LINK REF="STD-Xiao-2003" TYPE="STUDY">Xiao 2003</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>). Cochrane reviews should include all identified trials irrespective of what kind of outcome measures they report. In this way one can get an impression of the risks of outcome measure reporting bias - a bias component which seems to distort intervention effects similar to publication bias. Accordingly, three trials that do not contribute to our meta-analysis were included (<LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>; <LINK REF="STD-Xiao-2003" TYPE="STUDY">Xiao 2003</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>).</P>
<P>Second, we obtained additional relevant data by contacting principal investigators of included trials, thus reducing the risk of publication bias, ascertainment bias, and information bias (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>Third, our assessment of trial quality and hence risk of bias was based on separate specific domains and not on composite scores. The use of composite scores is discouraged as they are not supported by any empirical evidence and has several disadvantages including unreliable assessments of validity (<LINK REF="REF-Emerson-1990" TYPE="REFERENCE">Emerson 1990</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-J_x00fc_ni-1999" TYPE="REFERENCE">Jüni 1999</LINK>; <LINK REF="REF-Higgins-2009a" TYPE="REFERENCE">Higgins 2009a</LINK>). In a previous meta-analysis of TACE and TAE trials (<LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>), the authors made use of an <I>ad hoc</I> modified, non-validated version of the Jadad composite score (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), but did not provide any evidence for the validity of using this modified quality score. Importantly, the Jadad score <I>per se</I> is explicitly discouraged by The Cochrane Collaboration (<LINK REF="REF-Higgins-2009a" TYPE="REFERENCE">Higgins 2009a</LINK>). As well as suffering from the generic problems of scores, it does not cover one of the most important potential biases in randomised trials, ie, the adequacy of generation of the allocation sequence and allocation concealment (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>).</P>
<P>Fourth, we used the HR as the point estimate for all-cause mortality in our meta-analyses. The HR is the most appropriate summary statistic for survival data, since it takes into account both the whole follow-up period as well as participant censoring (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>; <LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). Nevertheless, the use of odds ratios when meta-analysing survival data is frequently observed, including a previous positive meta-analysis (<LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>). This approach suffers from the fact that only a few arbitrary time points are considered for analysis. This problem becomes highly relevant in the case of the first trial by Pelletier et al (<LINK REF="STD-Pelletier-1990" TYPE="STUDY">Pelletier 1990</LINK>). This trial - which we classified as a trial with low risk of selection bias - did in fact report a significant 1-year survival rate in favour of the control group compared with TACE (33% versus 24%, respectively). Nonetheless, after performing a meta-analysis of 1-year survival event rates showing no significant effect, Llovet et al excluded this trial from a subsequent &#8216;core group&#8217; meta-analysis of 2-year survival event rates due to its shorter follow-up period (<LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>).</P>
<P>Fifth, we considered the impact of randomised trials stopped early due to interim inspections or slow accrual on our meta-analyses by performing subgroup analyses. Trials stopped early for apparent benefit are becoming increasingly common, but are at risk of reporting treatment effects that are substantially larger than typical interventions that have been definitively studied (<LINK REF="REF-Montori-2005" TYPE="REFERENCE">Montori 2005</LINK>). This phenomenon may be attributed to chance alone (ie, stopping at 'random high') and is especially relevant if a low number of events has occurred (<LINK REF="REF-Hughes-1992" TYPE="REFERENCE">Hughes 1992</LINK>; <LINK REF="REF-Montori-2005" TYPE="REFERENCE">Montori 2005</LINK>; <LINK REF="REF-Schulz-2005" TYPE="REFERENCE">Schulz 2005</LINK>; <LINK REF="REF-Bassler-2008" TYPE="REFERENCE">Bassler 2008</LINK>). Simulation studies as well as empirical evidence demonstrate that trials which initially show a significant effect at interim inspections may later yield no significant effect (<LINK REF="REF-Montori-2008" TYPE="REFERENCE">Montori 2008</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>). Accordingly, methodologists recommend that relative risk reductions of more than 50% generated in early stopped trials with fewer than 100 events can easily be disregarded (<LINK REF="REF-Montori-2008" TYPE="REFERENCE">Montori 2008</LINK>). Unfortunately, authors of systematic reviews and meta-analyses frequently neglect the random error risk introduced from trials stopped early for apparent benefit, leading to a substantial impact on the meta-analysed results (<LINK REF="REF-Bassler-2007" TYPE="REFERENCE">Bassler 2007</LINK>). In addition, trials stopped early may also cause heterogeneity in meta-analysis of related trials, especially when a random-effects model is being used (<LINK REF="REF-Hughes-1992" TYPE="REFERENCE">Hughes 1992</LINK>). Of the nine trials included in our meta-analysis, three were stopped early using triangular test as stopping rule including the trial yielding the largest relative risk reductions of mortality (<LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>). Like other stopping rules, triangular test is at risk of overestimating the treatment effect (<LINK REF="REF-Hulot-2003" TYPE="REFERENCE">Hulot 2003</LINK>). Our sub-group analysis of trials stratified according to truncation status, showed that truncated trials yielded larger treatment effect sizes than non-truncated trials, carrying a weight of 40% of all trials in the meta-analysis.</P>
<P>Sixth, we supplemented our meta-analyses with trial sequential analysis adjusted for trial diversity (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). Methodological standards for meta-analyses should not be less rigorous than those for a single trial. Therfore, trial sequential monitoring boundaries should be applied to meta-analyses to reduce the risk of spurious significant findings due to sparse data and multiplicity. Trial sequential analysis addresses the random errors that may arise from repetitive analyses of accumulating data in cumulative meta-analyses. The primary goal of trial sequential analysis is to provide the required information size for the meta-analysis (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). The secondary goal is to evaluate if the cumulative Z -score cross the adjacent trial sequential monitoring boundaries (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). Our trial sequential analysis revealed that the total number of accrued participants to date (N = 645) is far from the calculated diversity-corrected required information size of 1028 patients (63% accrued until now). Thus, an additional 383 participants may be needed to demonstrate a potential effect on survival with &#945; = 0.05 and 80% power (&#946; = 0.20).</P>
<P>The weaknesses of our meta-analyses are closely related with the weaknesses in the individual trials. We observed a substantial statistical heterogeneity between trials. Besides methodological differences related to risk of bias, the trials demonstrated substantial clinical diversity, including Okuda stage, exclusion criteria, aetiology, and intervention scheme. We did not perform meta-regression due to the low number of available trials (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Deeks-2009" TYPE="REFERENCE">Deeks 2009</LINK>). We observed mostly insignificant differences in treatment effect sizes between subgroups, but it should be recalled that the test of interaction has limited power to detect interactions, even when the two estimates and P values seem very different (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>).</P>
<P>One trial in particular draws attention, since it has been cited extensively and forms the basis for the implementation of TACE due to its reported large beneficial effect based on a total of 46 events (ie, deaths) (<LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>). Indeed, it represented the largest effect estimate in favour of TACE in our meta-analysis. Besides early stopping for apparent benefit, baseline imbalances between the TACE group and the control group might have contributed further to the observed large beneficial effect. An almost twice as large proportion (23%) of participants in the control group were classified as advanced (stage C) HCC compared to the TACE group (13%), reflected by higher Child-Pugh scores, number of nodules, and inferior performance status. Thus, it can be argued that the control group represented a worse prognosis at baseline due to prognostic imbalance. Continuation of the trial might have reduced the risk of selection bias, hence yielding a more realistic effect estimate.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-10-01 18:23:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2010-10-01 18:23:21 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>There is not sufficient evidence to support or refute TACE or TAE for patients with unresectable HCC. Clinicians should conduct or await further trials with low risk of bias ('systematic error') and low risk of play of chance ('random error') before using TACE or TAE as standard loco-regional treatment for unresectable HCC.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-10-01 18:23:43 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>More adequately powered and bias-protected trials are needed, involving up to another 383 participants as calculated by bias- and heterogeneity-adjusted TSA. Only two trials with low risk of selection bias without co-interventions and without early stopping (ie, lowest overall risk of bias) have been performed, one evaluating TACE (<LINK REF="STD-Pelletier-1990" TYPE="STUDY">Pelletier 1990</LINK>) and one evaluating TAE (<LINK REF="STD-Bruix-1998" TYPE="STUDY">Bruix 1998</LINK>). Importantly, both trials suggest a possible detrimental effect on survival. Regarding tumour response, data assessors should be blinded and response criteria used should comply with the EASL modified RECIST criteria, since RECIST alone may underestimate complete and partial responses by not taking the extent of tumour necrosis into account (<LINK REF="REF-Forner-2009" TYPE="REFERENCE">Forner 2009</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-10-01 18:23:55 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We thank the investigators Drs. Bonnetain, Cheng, Pelletier, and Trinchet who kindly provided us with additional information and data on our request. We also thank Douglas Altman and Jørgen Hilden for useful comments on the pooling of hazard ratios from trials with two experimental groups. Further, we thank Bodil Als-Nielsen and Yan Gong for useful comments to the revised protocol. Dimitrinka Nikolova, Sarah Louise Klingenberg, and Kate Whitfield are thanked for their help of identifying trials. We acknowledge the work done by Petra Büchner-Steudel and colleagues, who prepared an earlier Cochrane Hepato-Biliary Group protocol in 2001-2002 (<LINK REF="REF-B_x00fc_chner_x002d_Steudel-2002" TYPE="REFERENCE">Büchner-Steudel 2002</LINK>). We, however, take full responsibility of the present version of this review.</P>
<P>Peer Reviewers: Jos Kleijnen, The Netherland. Tim Meyer, UK.<BR/>Contact Editor: Brian Davidson, UK.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-09-07 19:31:24 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Christian Gluud is Co-ordinating Editor of The Cochrane Hepato-Biliary Group.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-29 12:51:05 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Roberto S. Oliveri drafted an update of the protocol, originally prepared by Petra Büchner-Steudel et al (<LINK REF="REF-B_x00fc_chner_x002d_Steudel-2002" TYPE="REFERENCE">Büchner-Steudel 2002</LINK>), screened literature, extracted relevant data, assessed risk of bias of trials, contacted investigators, calculated point estimates, performed meta-analyses, and drafted and approved the final manuscript. Jørn Wetterslev performed TSA and reviewed and approved the final manuscript. Christian Gluud screened the literature, extracted relevant data, assessed risk of bias of trials, and reviewed and approved the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-09-07 18:34:05 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>TAE or TACE versus other intervention were excluded from the review and will be assessed in future in a separate review. Surgical co-interventions were excluded.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-04-01 16:16:44 +0200" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-03-10 14:23:49 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-03-10 14:23:49 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-Akamatsu-2004" MODIFIED="2008-04-01 16:16:44 +0200" MODIFIED_BY="[Empty name]" NAME="Akamatsu 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-04-01 16:08:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, et al</AU>
<TI>Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial</TI>
<SO>Liver International</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>625-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruix-1998" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Bruix 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-28 20:42:55 +0200" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="OTHER">
<AU>Bruix J, Llovet JM, Castells A, Bru C, Montanya X, Vilana R, et al</AU>
<TI>Treatment of hepatocellular carcinoma by transarterial embolization (TAE). A prospective placebo controlled trial [abstract]</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>249A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al</AU>
<TI>Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1578-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2004" MODIFIED="2010-07-27 12:46:01 +0200" MODIFIED_BY="[Empty name]" NAME="Cheng 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-07-27 12:46:01 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, et al</AU>
<TI>Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>5</NO>
<PG>305-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doffo_x00eb_l-2008" MODIFIED="2008-06-18 09:45:11 +0200" MODIFIED_BY="[Empty name]" NAME="Doffoël 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-06-18 09:45:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doffoël M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S, et al</AU>
<TI>Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402)</TI>
<SO>European Journal of Cancer</SO>
<YR>2008</YR>
<VL>44</VL>
<NO>4</NO>
<PG>528-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GETCH-1995" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="GETCH 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-28 20:43:11 +0200" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="OTHER">
<AU>Groupe Francophone d'Etude et de Traitement du Carcinome Hepatocellulaire</AU>
<TI>Treatment of unresectable hepatocellular carcinoma (HCC) by lipiodol-targeted transcatheter arterial chemoembolization (TACE). A multicenter randomized trial [abstract]</TI>
<SO>Hepatology</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>58A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire</AU>
<TI>A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>19</NO>
<PG>1256-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1995" MODIFIED="2010-07-27 12:44:00 +0200" MODIFIED_BY="[Empty name]" NAME="Li 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-07-27 12:44:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JQ, Zhang YQ, Zhang WZ, Yuan YF, Li GH</AU>
<TI>Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy</TI>
<SO>Journal of Cancer Research and Clinical Oncology</SO>
<YR>1995</YR>
<VL>121</VL>
<NO>6</NO>
<PG>364-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006" MODIFIED="2010-08-31 15:00:10 +0200" MODIFIED_BY="Christian Gluud" NAME="Li 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-31 15:00:10 +0200" MODIFIED_BY="Christian Gluud" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Li HX, et al</AU>
<TI>Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis - a randomized study</TI>
<SO>World Journal of Surgery</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>11</NO>
<PG>2004-11; discussion 2012-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-27 12:46:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Qian BY, et al</AU>
<TI>Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases</TI>
<SO>Digestive Surgery</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>4</NO>
<PG>235-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llovet-_x005b_TACE_x005d_-2002" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Llovet [TACE] 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al</AU>
<TI>Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9319</NO>
<PG>1734-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-27 16:28:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Llovet JM, Real MI, Vilana R, Planas R, Coll S, Aponte J, et al</AU>
<TI>Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HH) [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llovet-_x005b_TAE_x005d_-2002" MODIFIED="2010-11-07 14:24:29 +0100" MODIFIED_BY="[Empty name]" NAME="Llovet [TAE] 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-14 11:29:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al</AU>
<TI>Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9319</NO>
<PG>1734-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lo-2002" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Lo 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al</AU>
<TI>Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>5</NO>
<PG>1164-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelletier-1990" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Pelletier 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al</AU>
<TI>A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma</TI>
<SO>Journal of Hepatology</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>2</NO>
<PG>181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelletier-1998" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Pelletier 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-27 16:31:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al</AU>
<TI>Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization. A multicenter randomized trial [abstract]</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>A1292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al</AU>
<TI>Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC</TI>
<SO>Journal of Hepatology</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1</NO>
<PG>129-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2003" MODIFIED="2010-07-27 12:50:03 +0200" MODIFIED_BY="[Empty name]" NAME="Xiao 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-27 12:50:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao E, Li D, Shen S, Zhou S, Tan L, Wang Y, et al</AU>
<TI>Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells</TI>
<SO>Chinese Medical Journal</SO>
<YR>2003</YR>
<VL>116</VL>
<NO>2</NO>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-03-10 14:23:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bhattacharya-1995" MODIFIED="2008-09-26 16:18:00 +0200" MODIFIED_BY="Roberto S Oliveri" NAME="Bhattacharya 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-26 16:18:00 +0200" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE</AU>
<TI>Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma</TI>
<SO>Cancer</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>11</NO>
<PG>2202-10</PG>
<IDENTIFIERS MODIFIED="2008-09-26 16:18:00 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2010-03-11 11:49:46 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-11 11:49:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Zheng Y</AU>
<TI>Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>10</NO>
<PG>623-5</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:08:12 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2008" MODIFIED="2010-02-22 10:55:30 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-02-22 10:55:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al</AU>
<TI>Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>299</VL>
<NO>14</NO>
<PG>1669-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2003" MODIFIED="2010-03-11 11:50:42 +0100" MODIFIED_BY="[Empty name]" NAME="Jin 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-11 11:50:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin CB, Wu F, Wang ZB, Chen WZ, Zhu H</AU>
<TI>High intensity focused ultrasound therapy combined with transcatheter arterial chemoembolization for advanced hepatocellular carcinoma</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>4</NO>
<PG>401-3</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:08:46 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koda-2001" MODIFIED="2010-03-11 11:51:41 +0100" MODIFIED_BY="[Empty name]" NAME="Koda 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-11 11:51:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Koda M, Murawaki Y, Kawasaki H</AU>
<TI>The combination therapy of transcatheter arterial embolization and percutaneous ethanol injection for small hepatocellular carcinoma: randomized controlled study [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>Suppl 2</NO>
<PG>164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-11 11:51:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, et al</AU>
<TI>Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>6</NO>
<PG>1516-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" MODIFIED="2010-03-11 11:53:35 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-11 11:53:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li C, Xu D, Xu D, Li X, Zhang W, Liu Y</AU>
<TI>Hyperthermal lipiodol embolization and thermocoagulation for the treatment of primary hepatocellular carcinoma</TI>
<SO>Zhonghua Gan Zang Bing Za Zhi [Chinese Journal of Hepatology]</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>3</NO>
<PG>174-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2007" MODIFIED="2010-03-11 12:01:56 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-03-11 12:01:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang YC, Li Z-Y, Yang J-Z, Lin J, Li YZ, Ke X</AU>
<TI>Transcatheter arterial chemoembolization combined with CT-guided percutaneous intratumor ethanol injection for liver metastases</TI>
<SO>Chines Journal of Interventional Imaging and Therapy</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>1</NO>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1988" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Lin 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin DY, Liaw YF, Lee TY, Lai CM</AU>
<TI>Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1988</YR>
<VL>94</VL>
<NO>2</NO>
<PG>453-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2010-03-11 12:01:07 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-11 12:01:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Wu W, Li H</AU>
<TI>The intervention-therapeutic effect of lipiodol-arsenic emulsion for primary hepatic carcinoma</TI>
<SO>Jie Ry Fang She Xue Za Zhi [Journal of Interventional Radiology]</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>12</NO>
<PG>716-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2004" MODIFIED="2008-12-27 15:16:14 +0100" MODIFIED_BY="Roberto S Oliveri" NAME="Lu 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-27 15:16:12 +0100" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu W, Li YH, He XF, Chen Y, Zhao JB</AU>
<TI>Changes of liver function after transcatheter arterial chemoembolization with use of different dose of anticancer drugs in hepatocellular carcinoma</TI>
<SO>World Chinese Journal of Digestology</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2006" MODIFIED="2010-03-11 12:02:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-11 12:02:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al</AU>
<TI>Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial</TI>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>12</NO>
<PG>801-5</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:07:55 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lygidakis-1996" MODIFIED="2008-09-27 12:53:43 +0200" MODIFIED_BY="Roberto S Oliveri" NAME="Lygidakis 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-27 12:53:43 +0200" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lygidakis NJ, Tsiliakos S</AU>
<TI>Multidisciplinary management of hepatocellular carcinoma</TI>
<SO>Hepato-gastroenterology</SO>
<YR>1996</YR>
<VL>43</VL>
<NO>12</NO>
<PG>1611-9</PG>
<IDENTIFIERS MODIFIED="2008-09-27 12:53:43 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madden-1993" MODIFIED="2008-09-27 12:53:50 +0200" MODIFIED_BY="Roberto S Oliveri" NAME="Madden 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-09-27 12:53:50 +0200" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, et al</AU>
<TI>Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma</TI>
<SO>Gut</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>11</NO>
<PG>1598-600</PG>
<IDENTIFIERS MODIFIED="2008-09-27 12:53:50 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raoul-1997" MODIFIED="2011-03-10 14:23:49 +0100" MODIFIED_BY="[Empty name]" NAME="Raoul 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-27 16:48:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al</AU>
<TI>Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>5</NO>
<PG>1156-61</PG>
<IDENTIFIERS MODIFIED="2008-09-27 16:48:57 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-10 14:23:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al</AU>
<TI>Randomized controlled trial of chemoembolization vs intraarterial injection of 131 I labelled-iodized oil in the treatment of hepato-cellular carcinoma (HCC). Preliminary results [abstract]</TI>
<SO>Gastroenterology</SO>
<YR>1992</YR>
<VL>102</VL>
<PG>A874</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rougier-1993" MODIFIED="2010-03-11 12:11:06 +0100" MODIFIED_BY="[Empty name]" NAME="Rougier 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-03-11 12:11:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rougier P, Roche A, Pelletier G, Ducreux M, Pignon JP, Etienne JP</AU>
<TI>Efficacy of chemoembolization for hepatocellular carcinomas: experience from the Gustave Roussy Institute and the Bicetre Hospital</TI>
<SO>Journal of Surgical Oncology. Supplement</SO>
<YR>1993</YR>
<VL>3</VL>
<PG>94-6</PG>
<IDENTIFIERS MODIFIED="2008-09-27 16:49:07 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibata-2009" MODIFIED="2009-12-17 09:21:47 +0100" MODIFIED_BY="[Empty name]" NAME="Shibata 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-12-17 09:21:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K</AU>
<TI>Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?</TI>
<SO>Radiology</SO>
<YR>2009</YR>
<VL>252</VL>
<NO>3</NO>
<PG>905-13</PG>
<IDENTIFIERS MODIFIED="2009-12-17 09:21:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19567647"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuqun-2004" MODIFIED="2008-09-27 16:49:13 +0200" MODIFIED_BY="[Empty name]" NAME="Shuqun 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-27 16:49:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, et al</AU>
<TI>Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma</TI>
<SO>Hepato-gastroenterology</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>59</NO>
<PG>1445-7</PG>
<IDENTIFIERS MODIFIED="2008-09-27 16:49:13 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taniai-2006" MODIFIED="2008-09-27 16:49:22 +0200" MODIFIED_BY="[Empty name]" NAME="Taniai 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-27 16:49:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taniai N, Yoshida H, Mamada Y, Kawano Y, Mizuguchi Y, Akimaru K, et al</AU>
<TI>Is intraoperative adjuvant therapy effective for satellite lesions in patients undergoing reduction surgery for advanced hepatocellular carcinoma?</TI>
<SO>Hepato-gastroenterology</SO>
<YR>2006</YR>
<VL>53</VL>
<NO>68</NO>
<PG>258-61</PG>
<IDENTIFIERS MODIFIED="2008-09-27 16:49:22 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1993" MODIFIED="2010-03-11 12:13:09 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-03-11 12:12:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang GM</AU>
<TI>Combination of transcatheter hepatic artery infusion chemotherapy and embolization with whole liver moving strip irradiation for primary hepatic carcinoma: A randomized trial on 60 patients (abstract)</TI>
<SO>Chinese Medical Journal</SO>
<YR>1993</YR>
<VL>106</VL>
<PG>638</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1994" MODIFIED="2008-09-29 12:08:36 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Wang 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-29 12:08:36 +0200" MODIFIED_BY="dimitrinka nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang HL</AU>
<TI>Electrochemical therapy of 74 cases of liver cancer</TI>
<SO>The European Journal of Surgery. Supplement</SO>
<YR>1994</YR>
<VL>574</VL>
<PG>55-7</PG>
<IDENTIFIERS MODIFIED="2008-09-26 16:17:36 +0200" MODIFIED_BY="Roberto S Oliveri">
<IDENTIFIER TYPE="PUBMED" VALUE="7531022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2010-03-11 12:11:48 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-11 12:11:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS</AU>
<TI>Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation</TI>
<SO>Ai Zheng [Chinese Journal of Cancer]</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>7</NO>
<PG>827-33</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:09:26 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1995" MODIFIED="2010-08-31 15:06:54 +0200" MODIFIED_BY="Christian Gluud" NAME="Wu 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-08-31 15:06:54 +0200" MODIFIED_BY="Christian Gluud" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK</AU>
<TI>Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal</TI>
<SO>The British Journal of Surgery</SO>
<YR>1995</YR>
<VL>82</VL>
<NO>1</NO>
<PG>122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1998" MODIFIED="2010-03-11 12:14:25 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-11 12:14:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu P, Li L, Zhang Y</AU>
<TI>Transcatheter arterial chemo-embolization combined with CT-guided percutaneous intratumoral injection of lipiodol-ethanol for the treatment of primary hepatocellular carcinoma</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>5</NO>
<PG>391-3</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:09:35 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2006" MODIFIED="2010-03-11 12:15:06 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-11 12:15:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou QM, Wu PH, Zhao M, Wang QJ, Huang LX, Li YQ, et al</AU>
<TI>Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma</TI>
<SO>Ai Zheng [Chinese Journal of Cancer]</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1414-8</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:09:49 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2007" MODIFIED="2010-03-11 12:16:16 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-03-11 12:16:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Z-T, Lin X, Li G-H</AU>
<TI>Clinical study of arsenic trioxide-containing regimen in the treatment of middle or advanced hepatocellular carcinoma by TACE</TI>
<SO>Chinese Journal of Cancer Prevention and Treatment</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>14</NO>
<PG>1094-6 + 1103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-1998" MODIFIED="2010-03-11 12:17:07 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-11 12:17:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu K, Hu G, Liang W</AU>
<TI>Percutaneous transfemoral arterial implantation of drug delivery system for arterial infusion therapy of advanced primary hepatic carcinoma</TI>
<SO>Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>6</NO>
<PG>457-9</PG>
<IDENTIFIERS MODIFIED="2008-12-27 14:07:40 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-04 13:03:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aikata-2006" MODIFIED="2009-01-21 17:28:19 +0100" MODIFIED_BY="Roberto S Oliveri" NAME="Aikata 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-21 17:28:19 +0100" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="OTHER">
<AU>Aikata H, Shirakawa H, Takaki S, Uka K, Miki D, Yamashina K, et al</AU>
<TI>Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinomas</TI>
<SO>Hepatology</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>4 (Suppl 1)</NO>
<PG>494A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolondi-1996" MODIFIED="2009-01-21 14:41:46 +0100" MODIFIED_BY="[Empty name]" NAME="Bolondi 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-21 14:41:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolondi L, Sofia S, Piscaglia F, Gramantieri L, Siringo S, Livraghi T, et al</AU>
<TI>Efficacy of transarterial chemoembolization (TACE) associated to percutaneous ethanol injection (PEI) in the treatment of small hepatocellular carcinoma (HCC) [Abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>S118</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalla-Palma-1997" MODIFIED="2010-11-04 13:03:27 +0100" MODIFIED_BY="[Empty name]" NAME="Dalla Palma 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-04 13:03:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalla Palma L, Pozzi MR, Sponza M, Bartolozzi C, Lencioni R, Florio F, et al</AU>
<TI>Diagnostic imaging and interventional therapy in hepatocarcinoma. Multicenterstudy of 290 cases</TI>
<SO>La Radiologia Medica</SO>
<YR>1997</YR>
<VL>94</VL>
<NO>1-2</NO>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-2004" MODIFIED="2010-03-11 12:29:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ferrari 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-11 12:29:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari FS, Stella A, Gambacorta D, Magnolfi F, Fantozzi F, Pasquinucci P, et al</AU>
<TI>Treatment of large hepatocellular carcinoma: comparison between techniques and long term results</TI>
<SO>La Radiologia Medica</SO>
<YR>2004</YR>
<VL>108</VL>
<NO>4</NO>
<PG>356-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007" MODIFIED="2008-12-27 15:11:17 +0100" MODIFIED_BY="Roberto S Oliveri" NAME="Li 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-12-27 15:11:17 +0100" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X-Y, Yang LZ</AU>
<TI>Analysis of transcatheter arterial chemoembolization combined with percutaneous ethanol injection for hepatoma</TI>
<SO>Chinese Journal of Interventional Imaging and Therapy</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>4</NO>
<PG>269-72</PG>
<IDENTIFIERS MODIFIED="2008-12-27 15:11:17 +0100" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" MODIFIED="2008-09-28 20:48:29 +0200" MODIFIED_BY="Roberto S Oliveri" NAME="Wang 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-28 20:48:29 +0200" MODIFIED_BY="Roberto S Oliveri" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Shen W, Song M, Xu H</AU>
<TI>Results of combined treatment with transcatheter hepatic arterial chemoembolization and whole-liver irradiation with the moving strip technique in unresectable hepatocellular carcinoma</TI>
<SO>International Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>6</NO>
<PG>380-5</PG>
<IDENTIFIERS MODIFIED="2008-09-27 16:49:47 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2008" MODIFIED="2010-02-26 13:14:43 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-02-26 13:14:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang P, Liang M, Zhang Y, Shen B</AU>
<TI>Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC</TI>
<SO>Advances in Therapy</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>8</NO>
<PG>787-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-03-10 14:06:50 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-03-10 14:06:50 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2010-03-11 12:31:06 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bassler-2007" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Bassler 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bassler D, Ferreira-Gonzalez I, Briel M, Cook DJ, Devereaux PJ, Heels-Ansdell D, et al</AU>
<TI>Systematic reviewers neglect bias that results from trials stopped early for benefit</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2007</YR>
<VL>60</VL>
<NO>9</NO>
<PG>869-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bassler-2008" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Bassler 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G</AU>
<TI>Early stopping of randomized clinical trials for overt efficacy is problematic</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>3</NO>
<PG>241-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosch-2004" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Bosch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bosch FX, Ribes J, Diaz M, Cleries R</AU>
<TI>Primary liver cancer: worldwide incidence and trends</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<NO>Suppl 1</NO>
<PG>S5-S16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruix-2001" MODIFIED="2010-03-11 12:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Bruix 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al</AU>
<TI>Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>3</NO>
<PG>421-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00fc_chner_x002d_Steudel-2002" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Büchner-Steudel 2002" TYPE="COCHRANE_PROTOCOL">
<AU>Büchner-Steudel P, Patzies A, Behl S, Fleig WE</AU>
<TI>Transcatheter arterial chemoembolization for hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-09-29 15:01:46 +0200" MODIFIED_BY="Sarah Louise Klingenberg">
<IDENTIFIER MODIFIED="2008-09-29 15:01:46 +0200" MODIFIED_BY="Sarah Louise Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD003629.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Camm_x00e0_-2002" MODIFIED="2010-03-11 12:38:32 +0100" MODIFIED_BY="[Empty name]" NAME="Cammà 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al</AU>
<TI>Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials</TI>
<SO>Radiology</SO>
<YR>2002</YR>
<VL>224</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chlebowski-1984" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Chlebowski 1984" TYPE="JOURNAL_ARTICLE">
<AU>Chlebowski RT, Tong M, Weissman J, Block JB, Ramming KP, Weiner JM, et al</AU>
<TI>Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients</TI>
<SO>Cancer</SO>
<YR>1984</YR>
<VL>53</VL>
<NO>12</NO>
<PG>2701-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Choi-1990" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Choi 1990" TYPE="JOURNAL_ARTICLE">
<AU>Choi TK, Edward CS, Fan ST, Francis PT, Wong J</AU>
<TI>Results of surgical resection for hepatocellular carcinoma</TI>
<SO>Hepato-gastroenterology</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>2</NO>
<PG>172-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davila-2004" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Davila 2004" TYPE="JOURNAL_ARTICLE">
<AU>Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB</AU>
<TI>Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<NO>5</NO>
<PG>1372-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeAngelis-2009" MODIFIED="2010-03-11 12:39:19 +0100" MODIFIED_BY="[Empty name]" NAME="DeAngelis 2009" TYPE="OTHER">
<AU>DeAngelis CD, Fontanarosa PB</AU>
<TI>Retraction: Cheng B-Q, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299(14):1669-1677</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>301</VL>
<NO>18</NO>
<PG>1931</PG>
<IDENTIFIERS MODIFIED="2010-02-22 10:57:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19380477"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2003" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Deeks 2003" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al</AU>
<TI>Evaluating non-randomised intervention studies</TI>
<SO>Health Technology Assessment</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>27</NO>
<PG>iii-173</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2009" MODIFIED="2010-11-04 13:07:36 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2009" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-03-11 12:47:59 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2008-09-07 19:51:48 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</REFERENCE>
<REFERENCE ID="REF-Eisenhauer-2009" MODIFIED="2010-03-11 12:49:01 +0100" MODIFIED_BY="[Empty name]" NAME="Eisenhauer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al</AU>
<TI>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</TI>
<SO>European Journal of Cancer</SO>
<YR>2009</YR>
<VL>45</VL>
<NO>2</NO>
<PG>228-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Serag-1999" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="El-Serag 1999" TYPE="JOURNAL_ARTICLE">
<AU>El-Serag HB, Mason AC</AU>
<TI>Rising incidence of hepatocellular carcinoma in the United States</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>10</NO>
<PG>745-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Serag-2003" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="El-Serag 2003" TYPE="JOURNAL_ARTICLE">
<AU>El-Serag HB, Davila JA, Petersen NJ, McGlynn KA</AU>
<TI>The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>10</NO>
<PG>817-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Serag-2007" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="El-Serag 2007" TYPE="JOURNAL_ARTICLE">
<AU>El-Serag HB, Rudolph KL</AU>
<TI>Hepatocellular carcinoma: epidemiology and molecular carcinogenesis</TI>
<SO>Gastroenterology</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>7</NO>
<PG>2557-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emerson-1990" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Emerson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC</AU>
<TI>An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>5</NO>
<PG>339-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forner-2009" MODIFIED="2010-02-22 11:36:34 +0100" MODIFIED_BY="[Empty name]" NAME="Forner 2009" TYPE="JOURNAL_ARTICLE">
<AU>Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al</AU>
<TI>Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?</TI>
<SO>Cancer</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>3</NO>
<PG>616-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2010" MODIFIED="2010-11-04 13:09:14 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2010" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2010, Issue 10. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-11-04 13:09:37 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Colloboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009a" MODIFIED="2010-11-04 13:10:31 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1992" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Hughes 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hughes MD, Freedman LS, Pocock SJ</AU>
<TI>The impact of stopping rules on heterogeneity of results in overviews of clinical trials</TI>
<SO>Biometrics</SO>
<YR>1992</YR>
<VL>48</VL>
<NO>1</NO>
<PG>41-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hulot-2003" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Hulot 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hulot JS, Cucherat M, Charlesworth A, Van Veldhuisen DJ, Corvol JC, Mallet A, et al</AU>
<TI>Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2003</YR>
<VL>55</VL>
<NO>3</NO>
<PG>299-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2010-11-04 13:11:44 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-1999" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Jüni 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Witschi A, Bloch R, Egger M</AU>
<TI>The hazards of scoring the quality of clinical trials for meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1054-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2010-03-11 12:53:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llovet-2003a" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Llovet 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Burroughs A, Bruix J</AU>
<TI>Hepatocellular carcinoma</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<PG>1907-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llovet-2003b" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Llovet 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Bruix J, the Barcelona-Clínic Cancer Group</AU>
<TI>Systematic review of randomised trials for unresectable hepatocellular carcinoma: chemoembolization improves survival</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>429-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGlynn-2001" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="McGlynn 2001" TYPE="JOURNAL_ARTICLE">
<AU>McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JFJr</AU>
<TI>International trends and patterns of primary liver cancer</TI>
<SO>International Journal of Cancer</SO>
<YR>2001</YR>
<VL>94</VL>
<NO>2</NO>
<PG>290-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher R, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montori-2005" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Montori 2005" TYPE="JOURNAL_ARTICLE">
<AU>Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al</AU>
<TI>Randomized trials stopped early for benefit: a systematic review</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>294</VL>
<NO>17</NO>
<PG>2203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montori-2008" MODIFIED="2010-02-22 12:05:04 +0100" MODIFIED_BY="[Empty name]" NAME="Montori 2008" TYPE="BOOK_SECTION">
<AU>Montori V, Devereaux PJ, Schunemann H, Meade MO, Cook DJ, Guyatt G</AU>
<TI>Randomized trials stopped early for benefit</TI>
<SO>User's guide to the medical literature: a manual for evidence-based clinical practice</SO>
<YR>2008</YR>
<PG>153-65</PG>
<EN>2</EN>
<ED>Guyatt G, Rennie D, Meade MO, Cook DJ</ED>
<PB>The McGraw-Hill Companies</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagorney-1989" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Nagorney 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA</AU>
<TI>Primary hepatic malignancy: surgical management and determinants of survival</TI>
<SO>Surgery</SO>
<YR>1989</YR>
<VL>106</VL>
<NO>4</NO>
<PG>740-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paquet-1991" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Paquet 1991" TYPE="JOURNAL_ARTICLE">
<AU>Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Muting D, Rambach W</AU>
<TI>Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study</TI>
<SO>British Journal of Surgery</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>4</NO>
<PG>459-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1998" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Pogue 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pogue J, Yusuf S</AU>
<TI>Overcoming the limitations of current meta-analysis of randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9095</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2011-03-10 14:06:50 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sangiovanni-2004" MODIFIED="2008-09-29 17:10:00 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Sangiovanni 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al</AU>
<TI>Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4</NO>
<PG>1005-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2005" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Grimes DA</AU>
<TI>Multiplicity in randomised trials II: subgroup and interim analyses</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9471</NO>
<PG>1657-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Therasse-2000" MODIFIED="2010-12-08 10:38:47 +0100" MODIFIED_BY="[Empty name]" NAME="Therasse 2000" TYPE="JOURNAL_ARTICLE">
<AU>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al</AU>
<TI>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>3</NO>
<PG>205-16</PG>
<IDENTIFIERS MODIFIED="2010-12-08 10:38:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10655437"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2010-03-11 12:56:16 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2008-09-29 17:10:02 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2010-03-11 12:57:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2008-09-29 17:10:01 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-05-16 11:03:28 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-05-16 11:03:28 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-02-26 11:50:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akamatsu-2004">
<CHAR_METHODS MODIFIED="2008-09-29 13:25:16 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: March 1997 to April 2001.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:37 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 42.</LI>
<LI>Setting: hospital.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Arterial hyper-attenuation and portal hypo-attenuation on angiography under CT.</LI>
<LI>Hypervascular nodule, ie, positively enhanced on hepatic arteriography under CT.</LI>
</OL>
<LI>Eligibility criteria:</LI>
<OL>
<LI>A solitary HCC nodule.</LI>
<LI>No prior history of HCC treatment.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<LI>Mean age: 65.5</LI>
<LI>Sex (M/F): 27/15.</LI>
<LI>Country: Japan.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 4.</LI>
<LI>HCV: 32.</LI>
<LI>Alcohol: not reported.</LI>
<LI>Other: not reported.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: 18.</LI>
<LI>Cirrhosis: 21.</LI>
</OL>
<LI>Child-Pugh score</LI>
<OL>
<LI>A: N/A.</LI>
<LI>B/C: N/A.</LI>
</OL>
<LI>Okuda stage: not reported.</LI>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-29 12:57:31 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>
<B>Experimental</B>: TAE plus PTA regimen consisting of injection of lipiodol (&#8776;8 ml) followed by dispersion of gelatin sponges. Next, either injection of ethanol (&#8776;50 ml) or insertion of radio frequency ablation electrode (40 to 160 kW for 720 s for nodules 2 cm and 1440 s for nodules 3 cm in diameter).</LI>
<LI>
<B>Control</B>: PTA regimen consisting of either injection of ethanol (&#8776;50 ml) or insertion of radio frequency ablation electrode (40 to 160 kW for 720 s for nodules 2 cm and 1440 s for nodules 3 cm in diameter).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 12:57:53 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-06 13:06:31 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruix-1998">
<CHAR_METHODS MODIFIED="2008-09-29 13:25:28 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: persons evaluated between January 1992 and April 1994.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 80.</LI>
<LI>Setting: hospital.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Needle biopsy <I>and/or</I>
</LI>
<LI>Increased alfa-foetoprotein.</LI>
</OL>
<LI>Eligibility criteria:</LI>
<OL>
<LI>No previous treatment.</LI>
<LI>Tumour &gt; 4 cm and/or multinodular.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Age &gt; 75.</LI>
<LI>Uncontrolled liver disease decompensation (gastrointestinal bleeding, encephalopathy, bacterial infection).</LI>
<LI>Portal vein thrombosis.</LI>
<LI>Extrahepatic spread.</LI>
<LI>Any contraindication for an arterial procedure such as impairment of clotting tests (platelet count &lt; 50000/mm<SUP>3</SUP> or prothrombin activity &lt; 50%).</LI>
<LI>Renal failure.</LI>
<LI>Severe atheromatosis.</LI>
<LI>Advanced disease (Okuda stage III).</LI>
<LI>Performance status &gt; 2.</LI>
</OL>
<LI>Age: 63.</LI>
<LI>Se (M/F): 60/20.</LI>
<LI>Country: Spain.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 3.</LI>
<LI>HCV: 60.</LI>
<LI>Alcohol: 3.</LI>
<LI>Other: 14.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: 80.</LI>
</OL>
<LI>Child-Pugh score: exact numbers not reported.</LI>
<LI>Okuda stage</LI>
<OL>
<LI>I: 54.</LI>
<LI>II: 26.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<B>Experimental</B>: One TAE-session with consisting of embolisation with 1x1 mm gelatin cubes, combined with steel coil proximal occlusion in participants with unilobar disease. No chemotherapeutic agent was administered. Some participants were considered for additional sessions.</LI>
<LI>
<B>Control: </B>no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 12:59:48 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
<LI>Tumour response.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-26 19:08:32 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-16 11:03:28 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Cheng-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-16 11:03:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Participants underwent surgical resection of the liver.</LI>
<LI>Group B and C apparently comparable.</LI>
<LI>Paper has been requested from primary investigator for further assessment (and translation?). No response at the time of writing (31 August 2010).</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-08 19:14:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Doffo_x00eb_l-2008">
<CHAR_METHODS MODIFIED="2008-09-29 13:25:43 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: May 1995 to June 2002.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 123.</LI>
<LI>Setting: hospital.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Biopsy <I>or</I>
</LI>
<LI>Persistently elevated serum alpha-foetoprotein (&gt; 500 ng/ml) plus one typical imaging finding (ultrasonography, CT or MR).</LI>
</OL>
<LI>Eligibility criteria:</LI>
<OL>
<LI>Liver cirrhosis (histopathology, clinical presentation or laboratory findings).</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Age &gt; 75.</LI>
<LI>Advanced liver disease (Child-Pugh score C).</LI>
<LI>Advanced HCC (Okuda stage III).</LI>
<LI>Portal vein thrombosis (trunk and primary branches).</LI>
<LI>Arteriovenous shunting.</LI>
<LI>Extrahepatic metastases.</LI>
<LI>Renal failure (serum creatinine level &gt; 120 µmol/L or creatinine clearance &lt; 80 ml/s).</LI>
<LI>Platelet count &lt; 50 x 10<SUP>9</SUP>/L.</LI>
<LI>Prothrombin activity &lt; 50%.</LI>
<LI>Cardiac ejection fraction &lt; 35%.</LI>
</OL>
<LI>Mean age: 64.4.</LI>
<LI>Sex (M/F): 107/16.</LI>
<LI>Country: France.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 6.</LI>
<LI>HCV: 13.</LI>
<LI>Alcohol: 93</LI>
<LI>Other: 10.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: not reported.</LI>
</OL>
<LI>Child-Pugh score:</LI>
<OL>
<LI>A: 86.</LI>
<LI>B: 35.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 88.</LI>
<LI>II: 35.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-08 19:14:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>
<B>Experimental:</B> TACE plus tamoxifen regimen consisting of 1) injection of 50 mg epirubicin mixed with 15 ml lipiodol followed by embolization with gel-foam cubes. Repetition of TACE every 2 months until tumour stabilization; 2) a daily dose of 20 mg tamoxifen.</LI>
<LI>
<B>Control:</B> A daily dose of 20 mg tamoxifen.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-25 18:46:33 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause mortality.</LI>
<LI>Quality of life (Spitzer index).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-26 19:08:45 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-20 09:29:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GETCH-1995">
<CHAR_METHODS MODIFIED="2008-09-29 13:25:50 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: July 1990 to November 1992.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-11 13:13:16 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 96.</LI>
<LI>Setting: twenty-four centres in three countries (France, Belgium, Canada).</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Histologic/cytologic findings <I>or</I>
</LI>
<LI>Cirrhosis, liver tumour and serum alfa-fetoprotein &gt; 250 ng/ml.</LI>
</OL>
<LI>Elegibility criteria:</LI>
<OL>
<LI>Not specified explicitly, but probably all persons with diagnosed HCC without any exclusion criteria.</LI>
</OL>
<LI>Exclution criteria:</LI>
<OL>
<LI>Indication for surgery.</LI>
<LI>previous treatment for HCC.</LI>
<LI>Severe hepatic disease (one of the following: encephalopathy, gastrointestinal haemorrhage in the past month, clinical ascites, serum bilirubin &gt; 50 µmol/L, serum albumin &lt; 30 g/L).</LI>
<LI>Vascular contraindications to chemoembolization (such as portal obstruction of &gt; 3 segmental branches).</LI>
<LI>Contraindications to treatment with cisplatin.</LI>
<LI>Serum creatinine &#8805;120 µmol/L.</LI>
<LI>Extrahepatic metastasis.</LI>
</OL>
<LI>Mean age: 64.</LI>
<LI>Sex (M/F): 92/4.</LI>
<LI>Country: France, Belgium and Canada.</LI>
<LI>HCC characteristics:</LI>
</OL>
<OL>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 5.</LI>
<LI>HCV: 8.</LI>
<LI>Alcohol: 65.</LI>
<LI>Other: 9.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: 87.</LI>
</OL>
<LI>Child-Pugh score:</LI>
<OL>
<LI>A: 87. (ie, 100% of the cirrhotic participants).</LI>
<LI>B: 0.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 86.</LI>
<LI>II: 10.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-20 09:29:34 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<B>Experimental:</B> TACE with cisplatin (70 mg) emulsified in iodised oil (lipiodol) followed by embolisation with gelatin sponge (Gelfoam) particles, repeated every 2 months for a total of four courses.</LI>
<LI>
<B>Control:</B> no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 13:18:45 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
<LI>Tumour response.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-26 19:08:48 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Li-1995">
<CHAR_METHODS MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised to partial (radical or palliative) hepatectomy TACE versus partial (radical or palliative) hepatectomy only.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>140 patients with hepatocellular carcinoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>
<B>Experimental: </B>Partial (radical or palliative) hepatectomy + post-operative (3-4 weeks) TACE</LI>
<LI>
<B>Control:</B> Partial (radical or palliative) hepatectomy</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cancer recurrence.</P>
<P>Overall survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Trial described as randomised in abstract. No further description in main text.</LI>
<LI>No assessment of overall survival for all participants combined (70 vs 70): Survival data are split up into radical resections and palliative hepatectomies, respectively.</LI>
<LI>Survival data only reported as survival percentages. Data not suitable for inclusion in meta-analysis of hazard ratios.</LI>
<LI>Primary investigator has not been contacted due to difficulty of identification. </LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Li-2006">
<CHAR_METHODS MODIFIED="2010-08-31 14:55:45 +0200" MODIFIED_BY="Christian Gluud">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-31 14:55:35 +0200" MODIFIED_BY="Christian Gluud">
<P>131 patients with hepatocellular carcinoma and portal vein tumour thrombosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-31 14:54:40 +0200" MODIFIED_BY="Christian Gluud">
<OL>
<LI>
<B>Experimental:</B> Resection plus three courses of post-operative TACE starting after 4 weeks and with 2-weeks intervals.</LI>
<LI>
<B>Control:</B> Resection only.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Disease-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>No assessment of overall survival.</LI>
<LI>Participants apparently overlapping with Li 2006.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-07 14:24:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<CHAR_METHODS MODIFIED="2008-09-29 13:25:58 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: July 1996 to July 2000</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 75.</LI>
<LI>Setting: three hospital centres in the Barcelona area.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Needle biopsy <I>or</I>
</LI>
<LI>Two coincidental imaging techniques associated with increased alfa-fetoprotein.</LI>
</OL>
<LI>Elegibility criteria:</LI>
<OL>
<LI>Not explicitly stated but probably diagnosed HCC persons not fulfilling exclusion criteria.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Age &gt; 75.</LI>
<LI>Advanced liver disease (Child-Pugh score C).</LI>
<LI>Active gastrointestinal bleeding.</LI>
<LI>Encephalopathy.</LI>
<LI>Refractory ascites.</LI>
<LI>Presence of vascular invasion (including segmental portal obstruction).</LI>
<LI>Extrahepatic spread.</LI>
<LI>Portosystemic shunt.</LI>
<LI>Hepatofugal blood flow.</LI>
<LI>Any contradiction to arterial procedure such as impaired clotting tests. (platelet count &lt; 50x10<SUP>9</SUP>/L or prothrombin activity &lt; 50%).</LI>
<LI>Renal failure.</LI>
<LI>Severe atheromatosis.</LI>
<LI>Any contraindication to doxorubicin (serum bilirubin &gt; 85.5 µml/L, leucocyte count &lt; 3x10<SUP>9</SUP>/L, cardiac ejection fraction &lt; 50%).</LI>
<LI>Endstage tumoral disease.</LI>
</OL>
<LI>Age: 64.4.</LI>
<LI>Sex (M/F): 55/20.</LI>
<LI>Country: Spain.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Barcelona Clinic Liver Cancer (BCLC) staging classification</LI>
<OL>
<LI>Intermediate (stage B): 62</LI>
<LI>Advanced (stage C): 13</LI>
</OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 5.</LI>
<LI>HCV: 65.</LI>
<LI>Alcohol: 4.</LI>
<LI>Other: 1.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: not reported.</LI>
</OL>
<LI>Child-Pugh score:</LI>
<OL>
<LI>A: 52.</LI>
<LI>B: 23.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 49.</LI>
<LI>II: 26.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<B>Experimental:</B> One TACE-session at baseline with doxorubicin (bilirubin adjusted), lipiodol and mechanical obstruction. Repeated after 2 and 6 months, and then every 6 months.</LI>
<LI>
<B>Control:</B> no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-25 18:47:30 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause mortality.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-07 14:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>The control group is identical to the control group in the <LINK REF="STD-Llovet-_x005b_TAE_x005d_-2002" TYPE="STUDY">Llovet [TAE] 2002</LINK> reference.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-07 14:24:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<CHAR_METHODS MODIFIED="2008-09-29 13:26:04 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: July 1996 to July 2000.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 72.</LI>
<LI>Setting: three hospital centres in the Barcelona area.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Needle biopsy <I>or</I>
</LI>
<LI>Two coincidental imaging techniques associated with increased alfa-fetoprotein.</LI>
</OL>
<LI>Elegibility criteria:</LI>
<OL>
<LI>Not explicitly stated but probably diagnosed HCC persons not fulfilling exclusion criteria.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Age &gt; 75.</LI>
<LI>Advanced liver disease (Child-Pugh score C).</LI>
<LI>Active gastrointestinal bleeding.</LI>
<LI>Encephalopathy.</LI>
<LI>Refractory ascites.</LI>
<LI>Presence of vascular invasion (including segmental portal obstruction).</LI>
<LI>Extrahepatic spread.</LI>
<LI>Portosystemic shunt.</LI>
<LI>Hepatofugal blood flow.</LI>
<LI>Any contradiction to arterial procedure such as impaired clotting tests. (platelet count &lt; 50x10<SUP>9</SUP>/L or prothrombin activity &lt; 50%).</LI>
<LI>Renal failureSevere atheromatosis.</LI>
<LI>Any contraindication to doxorubicin (serum bilirubin &gt; 85.5 µml/L, leucocyte count &lt; 3x10<SUP>9</SUP>/L, cardiac ejection fraction &lt; 50%).</LI>
<LI>Endstage tumoral disease.</LI>
</OL>
<LI>Age: 65.</LI>
<LI>Sex (M/F): 53/19.</LI>
<LI>Country: Spain.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Barcelona Clinic Liver Cancer (BCLC) staging classification</LI>
<OL>
<LI>Intermediate (stage B): 55</LI>
<LI>Advanced (stage C): 17</LI>
</OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 3.</LI>
<LI>HCV: 62.</LI>
<LI>Alcohol: 5.</LI>
<LI>Other: 2.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: not reported.</LI>
</OL>
<LI>Child-Pugh class:</LI>
<OL>
<LI>A: 48.</LI>
<LI>B: 24.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 46.</LI>
<LI>II: 26.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<B>Experimental:</B> One TAE-session at baseline with gelfoam fragments, repeated after 2 and 6 months, and then every 6 months.</LI>
<LI>
<B>Control:</B> no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 13:21:02 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-07 14:24:11 +0100" MODIFIED_BY="[Empty name]">
<P>The control group is identical to the control group in the <LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK> reference.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-04 13:15:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lo-2002">
<CHAR_METHODS MODIFIED="2008-09-29 13:26:11 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: Screening of eligible persons started in March 1996. Time of data analyses not reported.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 13:15:11 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 79.</LI>
<LI>Setting: hospital.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Histology/cytology <I>or</I>
</LI>
<LI>Persistently elevated serum alfa-fetoprotein levels (&gt; 400 ng/ml) with typical imaging findings.</LI>
</OL>
<LI>Eligibility criteria:</LI>
<OL>
<LI>Not explicitly stated, but probably diagnosed HCC persons not fulfilling exclusion criteria.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Poor hepatic function (encephalopathy, ascites not controlled by diuretics, history of variceal bleeding within last three months, a serum total bilirubin level &gt; 50 µmol/L, serum albumin level &lt; 28 g/L, prothrombin time &gt; 4 s over the control).</LI>
<LI>Serum creatinine level &gt; 180 µmol/L.</LI>
<LI>History of previous treatment for the tumour or acute tumour rupture.</LI>
<LI>Presence of extrahepatic metastasis.</LI>
<LI>Vascular contraindications to chemoembolization (hepatic artery thrombosis, main portal vein thrombosis or arteriovenous shunting).</LI>
<LI>Poor performance status (Eastern Cooperative Oncology Group performance status rating grade 4).</LI>
</OL>
<LI>Age: 62.5.</LI>
<LI>Sex (M/F): 70/9.</LI>
<LI>Country: China (Hong Kong).</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 63.</LI>
<LI>HCV: not reported.</LI>
<LI>Alcohol: not reported.</LI>
<LI>Other: 16.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: not reported.</LI>
</OL>
<LI>Child-Pugh score:</LI>
<OL>
<LI>A: not reported.</LI>
<LI>B: not reported.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 37.</LI>
<LI>II: 42.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-25 18:54:49 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<B>Experimental:</B> TACE with cisplatin (median 10 mg), lipiodol, and gelatin-sponge pellets, repeated every 2 to 3 months.</LI>
<LI>
<B>Control:</B> no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 13:22:06 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
<LI>Tumour response.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-26 19:09:02 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelletier-1990">
<CHAR_METHODS MODIFIED="2008-09-29 13:22:26 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: February 1985 to February 1988.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 42.</LI>
<LI>Setting: Multicentre trial involving ten different hospitals.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Histology <I>or</I>
</LI>
<LI>Serum alfa-fetoprotein &gt; 500 ng/ml and a diagnosis of a liver tumour on radiological examinations.</LI>
</OL>
<LI>Eligibility criteria:</LI>
<OL>
<LI>Not stated explicitly but probably diagnosed HCC persons not fulfilling exclusion criteria.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Resectable HCC.</LI>
<LI>Spontaneous encephalopathy.</LI>
<LI>Portal vein thrombosis.</LI>
<LI>Previous portocaval anastomosis.</LI>
</OL>
<LI>Age: 64.</LI>
<LI>Sex (M/F): 37/5.</LI>
<LI>Country: France.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 3.</LI>
<LI>HCV: not reported.</LI>
<LI>Alcohol: 29.</LI>
<LI>Other: 6.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: 37.</LI>
</OL>
<LI>Child-Pugh score:</LI>
<OL>
<LI>A: not reported.</LI>
<LI>B: Note reported.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 11.</LI>
<LI>II: 22.</LI>
<LI>III: 9.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>
<B>Experimental:</B> TACE with doxorubicin (50 mg) followed by embolisation with gelatin sponge (Gelfoam) powder, repeated after 2, 6 and 12 months.</LI>
<LI>
<B>Control:</B> no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 13:23:05 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
<LI>Tumour response.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-07 19:25:55 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Patient inclusion was 41% of all HCC persons observed during the inclusion period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pelletier-1998">
<CHAR_METHODS MODIFIED="2008-09-29 13:23:22 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Study design: randomised clinical trial.</LI>
<LI>Total study duration: April 1991 to May 1995.</LI>
</OL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Total number: 73.</LI>
<LI>Setting: Multicentre trial involving eight hospital centres.</LI>
<LI>Diagnostic criteria:</LI>
<OL>
<LI>Histology/cytology.</LI>
</OL>
<LI>Eligibility criteria:</LI>
<OL>
<LI>Not explicitly stated but probably unresectable HCC not fulfilling exclusion criteria.</LI>
</OL>
<LI>Exclusion criteria:</LI>
<OL>
<LI>Indication for surgery.</LI>
<LI>Previous treatment of hepatocellular carcinoma (except surgery)</LI>
<LI>Portal vein occlusion (main trunk or one of the two branches).</LI>
<LI>Extrahepatic metastasis.</LI>
<LI>History of other cancer.</LI>
<LI>Age ±80 years.</LI>
<LI>Severe hepatic disease (encephalopathy, bilirubin ±30 mg/L, clinical ascites needing treatment, prothrombin activity 30% of normal).</LI>
<LI>Okuda stage 3.</LI>
<LI>WHO performance status stage 3 or 4.</LI>
<LI>Serum creatinine ±120 mmol/L.</LI>
<LI>Refusal to participate.</LI>
</OL>
<LI>Age: 66.</LI>
<LI>Sex (M/F): 62/11.</LI>
<LI>Country: France.</LI>
<LI>HCC characteristics:</LI>
<OL>
<LI>Aetiology</LI>
<OL>
<LI>HBV: 11.</LI>
<LI>HCV: 10.</LI>
<LI>HBV+HCV: 2.</LI>
<LI>Alcohol: 39.</LI>
<LI>Other: 3.</LI>
</OL>
<LI>Liver histology</LI>
<OL>
<LI>Chronic hepatitis: not reported.</LI>
<LI>Cirrhosis: 65.</LI>
</OL>
<LI>Child-Pugh score:</LI>
<OL>
<LI>A: 56.</LI>
<LI>B: 17.</LI>
</OL>
<LI>Okuda stage:</LI>
<OL>
<LI>I: 44.</LI>
<LI>II: 21.</LI>
</OL>
</OL>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-29 13:24:31 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>
<B>Experimental:</B> TACE plus tamoxifen regimen consisting of 1) TACE with cisplatin (2 mg/kg), lipiodol, purified egg lecithin, Gelfoam particles plus 2) tamoxifen (20 mg twice daily). TACE repeated every 3 months during the first year, thereafter every 4 months.</LI>
<LI>
<B>Control:</B> Tamoxifen (20 mg twice daily) and no treatment.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-29 13:24:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>All-cause mortality.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-07 15:52:24 +0200" MODIFIED_BY="Roberto S Oliveri"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Xiao-2003">
<CHAR_METHODS MODIFIED="2010-08-31 15:03:13 +0200" MODIFIED_BY="Christian Gluud">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-31 15:03:36 +0200" MODIFIED_BY="Christian Gluud">
<P>136 patients with hepatocellular carcinoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<OL>
<LI>
<B>Experimental: </B>Pre-operative TACE plus resection.</LI>
<LI>
<B>Control: </B>Resection.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Extent of apoptosis using histology</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>No assessment of overall survival.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>HCC = hepatocellular carcinoma.<BR/>TACE = transarterial chemoembolisation.<BR/>TAE = transarterial embolisation.<BR/>s = seconds.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-08-31 15:07:59 +0200" MODIFIED_BY="Christian Gluud" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-28 12:56:28 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Bhattacharya-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 12:56:28 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Intervention groups not eligible for inclusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:12:17 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:12:17 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>TAE/TACE was not performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-09 09:30:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-09 09:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>The trial fulfilled inclusion criteria, but has been excluded from further analyses due to a later retraction based on "concerns about the integrity of the<SUP> </SUP>data and the veracity of the report" (<LINK REF="REF-DeAngelis-2009" TYPE="REFERENCE">DeAngelis 2009</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:12:59 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Jin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:12:59 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>Groups are not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-11 13:13:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koda-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-11 13:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Althoug described as using a "randomised, sealed envelope method", an unreported number of PEI participants also received TACE. Given the small samples size(s) bias is introduced and data are significantly distorted.</P>
<P>Quote (from report): "In the PEI alone group, TACE was performed when five or more recurrent tumors were detected and PEI could not be performed" (P. 1518, 1st column, line 37).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Trial compares hyperthermal iodized oil embolisation versus chemoembolisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 15:04:14 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Liang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 15:04:14 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>Groups are not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>IInformation from the lead author demonstrates that the principal investigator was identical to the co-ordinator, who conducted the randomisation. Accordingly, we assess the randomisation as being conducted with inadequate allocation concealment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 15:06:41 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 15:06:41 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>TAE/TACE was not performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 15:17:32 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Lu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 15:17:32 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>Groups are not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:11:49 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Lu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:11:49 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>TAE/TACE was not performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-28 12:59:26 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Lygidakis-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 12:59:26 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Intervention groups not eligible for inclusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-28 13:19:46 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Madden-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 13:19:46 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Intervention groups not eligible for inclusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-28 13:20:28 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Raoul-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 13:20:28 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Intervention groups are not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-29 12:54:32 +0200" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Rougier-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-29 12:54:32 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>Single cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-17 09:23:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shibata-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-17 09:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>Inadequate randomisation (allocation according to day of the week)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-27 16:58:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shuqun-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-27 16:58:07 +0200" MODIFIED_BY="[Empty name]">
<P>Intervention groups are not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-28 13:22:51 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Taniai-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 13:22:51 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Intervention groups not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-28 13:26:29 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Wang-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 13:26:29 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Intervention groups not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-28 13:25:30 +0200" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Wang-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-28 13:25:30 +0200" MODIFIED_BY="Roberto S Oliveri">
<P>Single cohort study with irrelevant active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:14:58 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:14:58 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>A questionnaire survey, no randomisation, no investigation of overall survival.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-31 15:07:59 +0200" MODIFIED_BY="Christian Gluud" STUDY_ID="STD-Wu-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-31 15:07:59 +0200" MODIFIED_BY="Christian Gluud">
<P>Groups not considered comparable due to TACE-induced delay in the experimental group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:15:25 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Wu-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:15:25 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>Groups are not comparable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:16:02 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Zhou-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:16:02 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>TAE/TACe was not performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 15:19:48 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Zhou-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 15:19:48 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>TAE/TACE was not performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-27 14:11:17 +0100" MODIFIED_BY="Roberto S Oliveri" STUDY_ID="STD-Zhu-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-27 14:11:17 +0100" MODIFIED_BY="Roberto S Oliveri">
<P>TAE/TACE was not performed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-04 13:14:37 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aikata-2006">
<CHAR_METHODS MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Participants described as "divided randomly into two groups" without further details on generation of allocation sequence and allocation concealment.</P>
<P>Cisplatin was used as agent in TACE</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Forty-four participants with 44 hypervascular nodules smaller than 30 mm in diameter.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Compares TACE + RFA (21) versus RFA (23).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Total number of RFA electrode insertions and treatment sessions, local tumour response, survival, and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>Study exist in abstract form only.</P>
<P>The number of electrode insertions as well as treatment sessions needed to achieve complete necrosis of the lesions were significantly fewer in the TACE + RFA group compared with the RFA alone group.</P>
<P>Insufficient details on survival statistics, but log-rank p-value 0.9495 reported. Number of participants experiencing event not reported. Accordingly, appropriate summary data for survival cannot be calculated to be used in meta-analysis.</P>
<P>There was no significant difference regarding objective tumour response.</P>
<P>First author has been contacted by e-mail for further details regarding allocation generation and allocation concealment, number of events, and hazard ratio.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-03-09 09:25:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bolondi-1996">
<CHAR_METHODS MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Participants described as "randomly assigned" without further details on generation of allocation sequence and allocation concealment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Multicenter trial with 150 participants with small (&lt; 5cm) unifocal unresectable hepatocellular carcinoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Compares TACE + PEI (66) versus PEI (84). In the first group TACE was performed before PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>AFP levels, objective tumour response, and survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-09 09:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study exist in abstract form only. Data are described as preliminary.</P>
<P>Insufficient details on survival statistics, no p-value reported. Sufficient summary data cannot be calculated from the available data.</P>
<P>First author has been contacted by e-mail for further details regarding allocation generation and allocation concealment, number of events, and hazard ratio. No reply in the time or writing.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-04 13:14:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalla-Palma-1997">
<CHAR_METHODS MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Multi-arm study with four groups including TACE group and no treatment group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 13:14:34 +0100" MODIFIED_BY="[Empty name]">
<P>Participants described as undergoing "randomised protocols" in the English abstract. Italian text describes the use of a "lista di randomizzazione", which could or could not be a random table.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>TACE versus no treatment. Numbers?</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-26 11:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Text only in Italian with English abstract.</P>
<P>Exact number of participants to be determined.</P>
<P>Survival data summarised with Kaplan-Meier plot. Apparently no exact log-rank p-value, HR etc.</P>
<P>Author has been contacted by e-mail March 2009 about details regarding exact number of participants, generation of allocation sequence, allocation concealment, and relevant summary data. The author was also asked about the survival data by Bolondi et al. which is cited in the paper (Fig. 6). No reply by April 2009.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-04 13:14:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrari-2004">
<CHAR_METHODS MODIFIED="2010-11-04 13:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Described as "randomised" without any further details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>Cirrhotic participants were included in a four arm trial, including TACE PEI and PEI alone.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>TACE + PEI (19) versus PEI (20).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>Extent of tumour necrosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-04 13:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Significant survival advantage in favour of TACE + PEI (log-rank P 0.002).</P>
<P>However, the two groups differ significantly regarding baseline Child-Pugh scores: 16 out of 19 participants are class A in the TACE + PEI group compared to 8 out 20 participants in PEI group. Hence, substantial selection bias favouring the survival of TACE + PEI group since Child-Pugh score is a strong predictor.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>A full paper could not be retrieved for more detailed assessment. However, the title of the paper does not indicate a design involving more than one group of participants.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>A full paper could not be retrieved for more detailed assessment. However, the title of the paper does not indicate a design involving more than one group of participants.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2008">
<CHAR_METHODS MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>Trial with no description of randomisation in the abstract.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>78 participants with HCC.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>Four groups comparison including TACE+ RFA and RFA alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-02-26 11:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>A full paper is going to be retrieved for further assessment. Corresponding author has been contacted by e-mail for paper request. No response in the time of writing (April 2009).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-04-01 16:16:44 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-07 14:24:11 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-08-31 15:06:54 +0200" MODIFIED_BY="Christian Gluud" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-07 18:34:14 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>Quote: "A randomised sealed envelope method was used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-01 21:16:26 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>Quote (from report): "Randomization was performed using a computer-generated allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-30 19:40:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION>
<P>Quote (from correspondence): "We have used a computer ".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION>
<P>Quote (from correspondence): "(...) using computer".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 14:18:39 +0200" MODIFIED_BY="Christian Gluud" RESULT="UNKNOWN" STUDY_ID="STD-Li-1995">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 15:01:06 +0200" MODIFIED_BY="Christian Gluud" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-03 18:01:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION>
<P>Quote (from report): "Randomisation was done with a computer-generated allocation [...]"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-03 18:02:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION>
<P>Quote (from report): "Randomisation was done with a computer-generated allocation [...]"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-01 21:22:24 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="UNKNOWN" STUDY_ID="STD-Lo-2002">
<DESCRIPTION>
<P>Quote (from report): "Randomization [...] was performed [...] by drawing consecutively numbered sealed envelopes".</P>
<P>Comment: No description of method used for sequence generation. No additional information provided by corresponding author on request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-30 20:12:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION>
<P>Quote (from correspondence): "To generate the allocation sequence we used a random number table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-07 19:25:55 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION>
<P>Quote (from report): "Randomization was carried out [...] using a computer-generated list".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 15:04:17 +0200" MODIFIED_BY="Christian Gluud" RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-04 13:14:06 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-07 18:34:14 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="UNKNOWN" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>Quote: "A randomised sealed envelope method was used".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-04 13:14:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>Comment: Most likely done, due to reported details in a later review by the same investigators (<LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>, P. 431 and table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-08 10:39:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION>
<P>Quote (from correspondence): "Allocation was done centrally at the FFCD centre (Dijon) using computer".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION>
<P>Quote (from correspondence): "(...) centralized by phone to the Biostat. dpt.".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 14:18:46 +0200" MODIFIED_BY="Christian Gluud" RESULT="UNKNOWN" STUDY_ID="STD-Li-1995">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-31 15:01:13 +0200" MODIFIED_BY="Christian Gluud" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-26 10:18:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION>
<P>Quote (from report): "Randomisation was done with [...] sealed envelopes [...]".</P>
<P>Comment: It remains unclear whether envelopes were also sequentially numbered and opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-04 11:59:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION>
<P>Quote (from report): "Randomisation was done with [...] sealed envelopes [...]".</P>
<P>Comment: It remains unclear whether envelopes were also sequentially numbered and opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-01 21:22:51 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Lo-2002">
<DESCRIPTION>
<P>Quote (from report): "Randomization [...] was performed [...] by drawing consecutively numbered sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-07 19:25:55 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION>
<P>Quote (from report): "Each patient was randomly assigned to one of two groups using the sealed envelope technique".</P>
<P>Comment: Principal investigator has confirmed that envelopes were also sequentially numbered and opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-01 21:23:49 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION>
<P>Quote (from report): "[...] by telephone".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-04 11:45:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-08-31 15:06:54 +0200" MODIFIED_BY="Christian Gluud" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.01">
<NAME>All-cause mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Tumour response</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-26 11:50:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>Outcome not assessed quantitatively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-11 13:12:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>Participants and care givers not blinded due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-06 14:13:28 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-09-06 14:14:50 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-06 14:15:15 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="UNKNOWN" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION>
<P>Outcome not assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-09-06 14:15:03 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION>
<P> Quote (from report): "All computed tomographic scans were reviewed by two radiologists who were unaware of the patient's clinical data or treatment assignment".</P>
<P>Comment: data assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-09-06 14:15:26 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-31 14:18:59 +0200" MODIFIED_BY="Christian Gluud" RESULT="NO" STUDY_ID="STD-Li-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-08-31 14:19:03 +0200" MODIFIED_BY="Christian Gluud" RESULT="NO" STUDY_ID="STD-Li-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-31 15:01:15 +0200" MODIFIED_BY="Christian Gluud" RESULT="NO" STUDY_ID="STD-Li-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-08-31 15:01:17 +0200" MODIFIED_BY="Christian Gluud" RESULT="NO" STUDY_ID="STD-Li-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION>
<P>Data assessors (eg, radiologists) not reported of being blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-09-06 14:15:51 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION>
<P> Data assessors (eg, radiologists) not reported of being blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-08-03 18:00:25 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-07 15:45:13 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Lo-2002">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-09-07 15:44:29 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Lo-2002">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION>
<P> No description of data assessors (eg, radiologists) being blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-09-29 13:30:20 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION>
<P>Not performed due to nature of intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-06 14:12:07 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION>
<P>Outcome not assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-07-10 19:26:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION>
<P>Not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-31 15:04:39 +0200" MODIFIED_BY="Christian Gluud" RESULT="NO" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-08-31 15:04:41 +0200" MODIFIED_BY="Christian Gluud" RESULT="NO" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-10-04 11:45:18 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-10 18:12:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>No drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-29 12:59:52 +0200" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>No drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-10 18:45:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-10 18:53:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Li-1995">
<DESCRIPTION>
<P>No tumour response, adverse events or quality of life described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-20 09:30:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>No assessment of overall survival, tumour response, adverse events or quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-10 18:59:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-03 18:01:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-01 21:22:45 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Lo-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-10 19:23:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-10 19:27:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-04 11:45:18 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION>
<P>No assessment of overall survival, tumour response, adverse events or quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-10-04 11:45:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-26 20:07:41 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="YES" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>Mortality and causes of mortality as well as recurrence of HCC and complications are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:21:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>The authors of the trial report mortality and causes of mortality as well as recurrence of HCC and complications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:45:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:53:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION>
<P>The authors of the trial report mortality and causes of mortality as well as recurrence of HCC and complications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Li-1995">
<DESCRIPTION>
<P>No tumour response, adverse events or quality of life described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 09:30:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>No assessment of overall survival, tumour response, adverse events or quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION>
<P>Authors report all-cause mortality and adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION>
<P>Authors report all-cause mortality and adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lo-2002">
<DESCRIPTION>
<P>The authors of the trial report mortality, tumour response and adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION>
<P>The authors of the trial report mortality, tumour response and adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION>
<P>Authors report all-cause mortality, tumour response, and adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-04 11:45:19 +0200" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION>
<P>No assessment of overall survival, tumour response, adverse events or quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-07 14:24:11 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:15:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akamatsu-2004">
<DESCRIPTION>
<P>No truncation, no signs of academic or industry bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:21:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruix-1998">
<DESCRIPTION>
<P>No truncation, no signs of academic or industry bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:46:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doffo_x00eb_l-2008">
<DESCRIPTION>
<P>No truncation, no signs of academic or industry bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 11:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-GETCH-1995">
<DESCRIPTION>
<P>The trial was stopped early for lack of treatment benefit (crossing the lower triangular test border at the fifth interim inspection).</P>
<P>More participants in the control group had multinodular and large tumours and segmental obstruction which may have resulted in significant baseline imbalance between the two groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-20 09:30:34 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002">
<DESCRIPTION>
<P>The authors report that the sponsors of the study had no role in study design, data collect, data analysis, data interpretation, or writing of the manuscript. However, it remains unclear whether the sponsor of the chemotherapeutic agent had any role in the decision of when to terminate the trial.</P>
<P>Indeed, the trial was stopped early for apparent benefit (crossing the upper triangular test border at the ninth interim inspection) after a total of 46 events (deaths) had occurred (both arms combined). The observed effect estimate at this time point corresponded to a large relative risk reduction (RRR) of more than 50%. No head-to-head comparison of TACE versus TAE was performed after stopping the TACE-arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 14:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002">
<DESCRIPTION>
<P>The authors report that the sponsors of the study had no role in study design, data collect, data analysis, data interpretation, or writing of the manuscript. However, it remains unclear whether the sponsor of the chemotherapy (doxorubicin) had any role in the decision of when to terminate the trial.</P>
<P>The trial was designed for interim inspections using triangular test. It was stopped prematurely while still accumulating data within the triangular borders ('under-running') due to the results of the other active (TACE) arm (<LINK REF="STD-Llovet-_x005b_TACE_x005d_-2002" TYPE="STUDY">Llovet [TACE] 2002</LINK>). At this time point a total of 50 events (deaths) had occurred (both arms combined). Accordingly, the null hypothesis could neither be accepted nor rejected. Nevertheless, the authors reported a HR, but it remains unclear whether or not this value was adjusted for 'under-running'. No head-to-head comparison of TAE versus TACE was performed after stopping the TACE-arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 19:19:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lo-2002">
<DESCRIPTION>
<P>No truncation, no signs of academic or industry bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 19:23:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pelletier-1990">
<DESCRIPTION>
<P>No truncation, no signs of academic or industry bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-07 19:21:50 +0200" MODIFIED_BY="Roberto S Oliveri" RESULT="NO" STUDY_ID="STD-Pelletier-1998">
<DESCRIPTION>
<P>A sample size of 80 persons was calculated, but the study was stopped after 73 persons due to low accrual rate.</P>
<P>No signs of academic or industry bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Xiao-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-05-16 11:01:22 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-05-16 11:01:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2010-10-01 18:24:52 +0200" MODIFIED_BY="Dimitrinka Nikolova">Tumour response</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Response evaluation</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Evaluation follow-up</P>
</TH>
<TD VALIGN="TOP">
<P>
<B>Results</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pelletier 1990</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response was evaluated using both tumour size and &#945;-foetoprotein levels and was classified in the following categories:</P>
<OL>
<LI>Complete response (disappearance of liver tumour on both echography and arteriography and restoration of normal &#945;-foetoprotein levels).</LI>
<LI>Partial response (Decrease in tumour size and &#8805;50% decrease in &#945;-foetoprotein levels).</LI>
</OL>
</TD>
<TD VALIGN="TOP">
<P>Not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>In the TACE group complete and partial tumour response were observed in four (19%) and three (14%) participants, respectively. Duration of responses lasted between 2 and 12 months. No tumour response was observed in the control group.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>GETCH 1995</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response was evaluated using tumour size and &#945;-foetoprotein levels separately.</P>
<P>Response according to tumour size was classified as:</P>
<OL>
<LI>&gt;50% decrease.</LI>
<LI>25%-50% decrease.</LI>
<LI>&lt;25% decrease or &lt;25% increase (stable)</LI>
<LI>&#8805;25% increase.</LI>
</OL>
<P>Response according to &#945;-foetoprotein levels was classified as:</P>
<OL>
<LI>&gt;50% decrease.</LI>
<LI>25%-50% decrease.</LI>
<LI>&lt;25% decrease or &lt;25% increase (stable)</LI>
<LI>&#8805;25% increase.</LI>
</OL>
</TD>
<TD VALIGN="TOP">
<P>Baseline abdominal CT scans and measurements of serum &#945;-foetoprotein were carried out before TACE followed by post-chemoembolisation control measurements every two months during the first year, and thereafter every four months.</P>
</TD>
<TD VALIGN="TOP">
<P>TACE group (N = 43):</P>
<P>Decreased &gt;50%: 16%</P>
<P>Decreased 25-50%: 37%</P>
<P>Stable disease: 37%</P>
<P>Increased &#8805;25%: 9%</P>
<P/>
<P>Control group (N = 38):</P>
<P>Decreased &gt;50%: 5%</P>
<P>Decreased 25-50%: 8%</P>
<P>Stable disease: 37%</P>
<P>Increased &#8805;25%: 50%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bruix 1998</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response was evaluated using tumour size. It is unclear whether non-enhanced tumoral areas (reflecting tissue necrosis) were excluded from final calculation of tumour response.</P>
<P>Response was classified as:</P>
<OL>
<LI>Complete response (no evidence of neoplastic disease)</LI>
<LI>Partial response (&gt;50% reduction of total tumour load)</LI>
<LI>No change (reduction of &lt;50% or increase of &lt;25%)</LI>
<LI>Progressive disease (&#8805;25%).</LI>
</OL>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Tumour size was assessed by dynamic CT scan within the first month after treatment and thereafter every six months.</P>
</TD>
<TD VALIGN="TOP">
<P>TAE group (N = 40):</P>
<P>Complete response: 0%</P>
<P>Partial response: 55%</P>
<P>Stable disease: 35%</P>
<P>Progression: 10%</P>
<P/>
<P>Control group (N = 40):</P>
<P>Not reported.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pelletier 1998</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response was evaluated using tumour size and was classified as:</P>
<OL>
<LI>Complete response (complete disappearance of all tumour lesions)</LI>
<LI>Partial response (&gt;50% decrease in tumour size)</LI>
</OL>
<P>Stable disease or progression were not defined.</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response only available for 45 participants.</P>
<P>TACE plus tamoxifen group:</P>
<P>Complete response: 0</P>
<P>Partial response &gt;50%: 9 participants</P>
<P>Stable disease and progression: not reported.</P>
<P/>
<P>Tamoxifen group:</P>
<P>Complete response: 0</P>
<P>Partial response &gt;50%: 2 participants</P>
<P>Stable disease and progression: not reported.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Llovet 2002 (TAE)</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response was evaluated using tumour size and was classified as:</P>
<P>Complete response (no evidence of neoplastic disease)</P>
<P>Partial response (&gt;50% reduction of total tumour load)</P>
<P>No change (reduction of &lt;50% or increase of &lt;25%)</P>
<P>Progressive disease (&#8805;25%).</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Tumour size was evaluated by contrast-enhanced spiral CT every six months.</P>
</TD>
<TD VALIGN="TOP">
<P>14 participants achieved complete or partial response after TACE. Further details not reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Llovet 2002 (TACE)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Tumour response was evaluated using tumour size and was classified as:</P>
<P>Complete response (no evidence of neoplastic disease)</P>
<P>Partial response (&gt;50% reduction of total tumour load)</P>
<P>No change (reduction of &lt;50% or increase of &lt;25%)</P>
<P>Progressive disease (&#8805;25%).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Tumour size was evaluated by contrast-enhanced spiral CT every six months.</P>
</TD>
<TD VALIGN="TOP">
<P>16 participants achieved complete or partial response after TAE. Further details not reported.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Lo 2002</P>
</TD>
<TD VALIGN="TOP">
<P>Tumour response was evaluated using tumour size and ?-foetoprotein levels. Tumour size was defined as the product of the two largest diameters of the lesion. Response was classified as:</P>
<OL>
<LI>Complete response (complete disappearing of tumour on imaging or normalization of alfa-foetoprotein levels)</LI>
<LI>Major response (&gt;50% decrease in tumour size or AFP compared to baseline)</LI>
<LI>Minor response (&lt;50% but &gt;25% decrease in tumour size or AFP compared to baseline)</LI>
<LI>Stabilization (&lt; 25% decrease or &lt;25% increase in tumour size or AFP compared to baseline)</LI>
<LI>Progression (&gt;25% increase in tumour size or AFP compared to baseline)</LI>
</OL>
<P>Objective response was defined as the sum of complete and major responses.</P>
<P>CT was performed every three months and &#945;-foetoprotein levels were measured every month.</P>
</TD>
<TD VALIGN="TOP">
<P>CT was performed every three months and &#945;-foetoprotein levels were measured every month.</P>
</TD>
<TD VALIGN="TOP">
<P>TACE group (N = 28):</P>
<P>Complete response: 0%</P>
<P>Major response: 39%</P>
<P>Minor response: 21%</P>
<P>Stabilization: 25%</P>
<P>Progression: 14%</P>
<P/>
<P>Control group (N = 18):</P>
<P>Complete response: 0%</P>
<P>Major response: 6%</P>
<P>Minor response: 11%</P>
<P>Stabilization: 33%</P>
<P>Progression: 50%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>TACE or TAE versus control</NAME>
<IV_OUTCOME CHI2="11.437042802375064" CI_END="1.0152940644662924" CI_START="0.6388775905978772" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.8053872519816481" ESTIMABLE="YES" I2="30.051848731923197" I2_Q="74.8465746586894" ID="CMP-001.01" LOG_CI_END="0.006591847252716525" LOG_CI_START="-0.19458234500351262" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09399524887539805" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.17814383185094695" P_Q="0.04616403111759404" P_Z="0.06702292941664868" Q="3.9756016782241392" RANDOM="YES" SCALE="6.4" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.03611463556036016" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.8315202407177031">
<NAME>All-cause mortality (subgroup: risk of selection bias)</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="6.819710493072754" CI_END="1.102916797804381" CI_START="0.707544485492483" DF="6" EFFECT_SIZE="0.8833814002137003" ESTIMABLE="YES" I2="12.01972567465129" ID="CMP-001.01.01" LOG_CI_END="0.04254275122771635" LOG_CI_START="-0.1502462495187962" LOG_EFFECT_SIZE="-0.05385174914553994" MODIFIED="2010-02-22 10:55:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33784282333042326" P_Z="0.2735370564669196" STUDIES="7" TAU2="0.010917196404051461" TOTAL_1="0" TOTAL_2="0" WEIGHT="81.69104179387726" Z="1.094953430133936">
<NAME>Trials with low risk of selection bias</NAME>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" MODIFIED="2010-02-17 11:11:46 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="15" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.586362506826699"/>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2009-05-19 10:07:00 +0200" MODIFIED_BY="Roberto S Oliveri" ORDER="21" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.618476391099787"/>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" MODIFIED="2010-02-17 11:11:44 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="60" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.66336656246321"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" MODIFIED="2010-02-17 11:11:44 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="59" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.511567040696519"/>
<IV_DATA CI_END="1.3415374031044" CI_START="0.24219398765689884" EFFECT_SIZE="0.5700107834495196" ESTIMABLE="YES" ESTIMATE="-0.5621" LOG_CI_END="0.12760278564410968" LOG_CI_START="-0.6158366421997454" LOG_EFFECT_SIZE="-0.24411692827781786" MODIFIED="2010-02-17 11:11:40 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="58" SE="0.4367" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.1565224775062015"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" MODIFIED="2008-08-05 08:54:57 +0200" MODIFIED_BY="[Empty name]" ORDER="63" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.081677962449273"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" MODIFIED="2008-09-01 20:00:38 +0200" MODIFIED_BY="Roberto S Oliveri" ORDER="18" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.073068852835574"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.4742664281315371" CI_END="0.8309716368316469" CI_START="0.34329909002554493" DF="1" EFFECT_SIZE="0.5341084222902144" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.08041379953445024" LOG_CI_START="-0.4643273477464266" LOG_EFFECT_SIZE="-0.27237057364043843" MODIFIED="2010-02-17 11:30:30 +0100" MODIFIED_BY="Roberto S Oliveri" NO="2" P_CHI2="0.49103096982555394" P_Z="0.005418762749123485" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.30895820612274" Z="2.781024620100243">
<NAME>Trials with high risk of selection bias</NAME>
<IV_DATA CI_END="2.3857158333567865" CI_START="0.24850328379160838" EFFECT_SIZE="0.7699728688614912" ESTIMABLE="YES" ESTIMATE="-0.2614" LOG_CI_END="0.3776187128654618" LOG_CI_START="-0.6046678680044819" LOG_EFFECT_SIZE="-0.11352457756951001" MODIFIED="2010-02-17 11:30:30 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="19" SE="0.577" STUDY_ID="STD-Akamatsu-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.7839206151712825"/>
<IV_DATA CI_END="0.8082298251912816" CI_START="0.30934714805140706" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09246512731950418" LOG_CI_START="-0.5095538834947836" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2009-05-19 10:06:43 +0200" MODIFIED_BY="Roberto S Oliveri" ORDER="21" SE="0.245" STUDY_ID="STD-Lo-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.525037590951456"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.548739232958582" CI_END="1.0271220390857014" CI_START="0.6415875506116211" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.8117811978829079" ESTIMABLE="YES" I2="30.728369230391376" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.011622048030267585" LOG_CI_START="-0.19274407170820027" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09056101183896635" MODIFIED="2010-02-22 11:11:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17250195266651125" P_Q="0.5027717688293989" P_Z="0.08237966283335733" Q="0.44908090340340373" RANDOM="YES" SCALE="6.4" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.03784511580529208" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="1.7370425375304455">
<NAME>All-cause mortality (subgroup: TAE or TACE)</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="9.329611606095993" CI_END="1.0562873980076117" CI_START="0.5837623750198386" DF="5" EFFECT_SIZE="0.7852520870169332" ESTIMABLE="YES" I2="46.407200952149104" ID="CMP-001.02.01" LOG_CI_END="0.023782098488698663" LOG_CI_START="-0.23376389983762808" LOG_EFFECT_SIZE="-0.10499090067446465" MODIFIED="2010-02-22 11:11:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09661760197997427" P_Z="0.11004447831933402" STUDIES="6" TAU2="0.06138700633506416" TOTAL_1="0" TOTAL_2="0" WEIGHT="77.5550719938617" Z="1.5979932545147828">
<NAME>TACE</NAME>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" ORDER="33" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.78066968965158"/>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" MODIFIED="2008-11-18 22:06:02 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="32" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.856574209950557"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" MODIFIED="2008-11-18 22:06:02 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="31" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.649268335312876"/>
<IV_DATA CI_END="0.8082298251912816" CI_START="0.30934714805140706" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09246512731950418" LOG_CI_START="-0.5095538834947836" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2010-02-22 11:11:52 +0100" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.245" STUDY_ID="STD-Lo-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.724579463631322"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" ORDER="30" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.267851004049227"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" ORDER="29" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.276129291266148"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.6934657365754577" CI_END="1.4212264781582542" CI_START="0.6159738469023202" DF="2" EFFECT_SIZE="0.9356486205144409" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.15266329001550386" LOG_CI_START="-0.21043772677571487" LOG_EFFECT_SIZE="-0.02888721838010549" MODIFIED="2010-02-22 11:11:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.42881392507456517" P_Z="0.755148739748253" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="22.444928006138284" Z="0.3118576099780257">
<NAME>TAE</NAME>
<IV_DATA CI_END="4.673165530670847" CI_START="0.23906096261459034" EFFECT_SIZE="1.0569633154558846" ESTIMABLE="YES" ESTIMATE="0.0554" LOG_CI_END="0.6696111646715869" LOG_CI_START="-0.6214913360767066" LOG_EFFECT_SIZE="0.02405991429744018" MODIFIED="2010-02-22 11:11:51 +0100" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.7584" STUDY_ID="STD-Akamatsu-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.3508310703420716"/>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" MODIFIED="2008-11-18 22:05:09 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="25" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.788764842069057"/>
<IV_DATA CI_END="1.3415374031044" CI_START="0.24219398765689884" EFFECT_SIZE="0.5700107834495196" ESTIMABLE="YES" ESTIMATE="-0.5621" LOG_CI_END="0.12760278564410968" LOG_CI_START="-0.6158366421997454" LOG_EFFECT_SIZE="-0.24411692827781786" MODIFIED="2008-11-18 22:06:05 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="27" SE="0.4367" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.305332093727155"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.819710493072754" CI_END="1.102916797804381" CI_START="0.707544485492483" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.8833814002137003" ESTIMABLE="YES" I2="12.01972567465129" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.04254275122771635" LOG_CI_START="-0.1502462495187962" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05385174914553994" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" P_CHI2="0.33784282333042326" P_Q="0.9873975694353957" P_Z="0.2735370564669196" Q="2.494965961346347E-4" RANDOM="YES" SCALE="6.4" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.010917196404051463" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="1.094953430133936">
<NAME>All-cause mortality (subgroup: TAE or TACE with low risk of selection bias)</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.102921791125875" CI_END="1.144704915001573" CI_START="0.6673938399021366" DF="4" EFFECT_SIZE="0.8740532070633622" ESTIMABLE="YES" I2="21.61353507404106" ID="CMP-001.03.01" LOG_CI_END="0.05869354754665117" LOG_CI_START="-0.1756178062351017" LOG_EFFECT_SIZE="-0.05846212934422525" MODIFIED="2010-12-08 10:08:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2768992565719267" P_Z="0.328051473038545" STUDIES="5" TAU2="0.020587774139011188" TOTAL_1="0" TOTAL_2="0" WEIGHT="77.10970669949785" Z="0.978046228873157">
<NAME>TACE</NAME>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="25.749360455809807"/>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.05225692807482"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="53" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.62066894550467"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.975000200303326"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="52" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.712420169805226"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.6654047164724757" CI_END="1.6066035396414846" CI_START="0.4704046201076633" DF="1" EFFECT_SIZE="0.8693409732255116" ESTIMABLE="YES" I2="39.95453536854883" ID="CMP-001.03.02" LOG_CI_END="0.20590871945862652" LOG_CI_START="-0.3275284214612323" LOG_EFFECT_SIZE="-0.0608098510013029" MODIFIED="2010-12-08 10:08:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19687524018668145" P_Z="0.6549781580653233" STUDIES="2" TAU2="0.08562898000000008" TOTAL_1="0" TOTAL_2="0" WEIGHT="22.890293300502165" Z="0.4468572160621508">
<NAME>TAE</NAME>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="59" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.52970485219225"/>
<IV_DATA CI_END="1.3415374031044" CI_START="0.24219398765689884" EFFECT_SIZE="0.5700107834495196" ESTIMABLE="YES" ESTIMATE="-0.5621" LOG_CI_END="0.12760278564410968" LOG_CI_START="-0.6158366421997454" LOG_EFFECT_SIZE="-0.24411692827781786" MODIFIED="2010-12-08 10:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="58" SE="0.4367" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.360588448309917"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.548739232958583" CI_END="1.0271220390857014" CI_START="0.641587550611621" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.8117811978829078" ESTIMABLE="YES" I2="30.728369230391383" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.011622048030267585" LOG_CI_START="-0.19274407170820032" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09056101183896641" MODIFIED="2010-02-22 10:55:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.17250195266651125" P_Q="0.3719600575196431" P_Z="0.08237966283335729" Q="0.7971061065904634" RANDOM="YES" SCALE="5.32" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0378451158052921" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.7370425375304457">
<NAME>All-cause mortality (subgroup: co-interventions)</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.32074662728326" CI_END="1.0741476428862824" CI_START="0.5275856773124968" DF="5" EFFECT_SIZE="0.7527980550624326" ESTIMABLE="YES" I2="51.55389255674272" ID="CMP-001.04.01" LOG_CI_END="0.031063979765662948" LOG_CI_START="-0.2777070030206316" LOG_EFFECT_SIZE="-0.12332151162748432" MODIFIED="2010-02-17 11:33:43 +0100" MODIFIED_BY="Roberto S Oliveri" NO="1" P_CHI2="0.0666407758053078" P_Z="0.11744259956231833" STUDIES="6" TAU2="0.0973712821495799" TOTAL_1="0" TOTAL_2="0" WEIGHT="65.5923699487402" Z="1.5655986785273492">
<NAME>Without co-intervention</NAME>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" ORDER="44" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.788764842069059"/>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" ORDER="43" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.856574209950557"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" ORDER="42" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.649268335312878"/>
<IV_DATA CI_END="1.3415374031044" CI_START="0.24219398765689884" EFFECT_SIZE="0.5700107834495196" ESTIMABLE="YES" ESTIMATE="-0.5621" LOG_CI_END="0.12760278564410968" LOG_CI_START="-0.6158366421997454" LOG_EFFECT_SIZE="-0.24411692827781786" ORDER="41" SE="0.4367" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.305332093727157"/>
<IV_DATA CI_END="0.8082298251912816" CI_START="0.30934714805140706" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09246512731950418" LOG_CI_START="-0.5095538834947836" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2010-02-17 11:33:43 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="39" SE="0.245" STUDY_ID="STD-Lo-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.724579463631327"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" ORDER="40" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.267851004049229"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.030018093311229264" CI_END="1.262339989533699" CI_START="0.6874187781461684" DF="2" EFFECT_SIZE="0.9315343328135053" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.10117634040127046" LOG_CI_START="-0.16277860846025366" LOG_EFFECT_SIZE="-0.030801134029491584" MODIFIED="2010-02-22 10:55:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9851030297641523" P_Z="0.647369318213667" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="34.4076300512598" Z="0.45741982592995756">
<NAME>With co-intervention</NAME>
<IV_DATA CI_END="4.673165530670847" CI_START="0.23906096261459034" EFFECT_SIZE="1.0569633154558846" ESTIMABLE="YES" ESTIMATE="0.0554" LOG_CI_END="0.6696111646715869" LOG_CI_START="-0.6214913360767066" LOG_EFFECT_SIZE="0.02405991429744018" MODIFIED="2010-02-17 11:33:48 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="35" SE="0.7584" STUDY_ID="STD-Akamatsu-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.350831070342072"/>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" ORDER="37" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.780669689651578"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" ORDER="55" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.27612929126615"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.819710493072753" CI_END="1.102916797804381" CI_START="0.707544485492483" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.8833814002137003" ESTIMABLE="YES" I2="12.01972567465128" I2_Q="69.6835999804177" ID="CMP-001.05" LOG_CI_END="0.04254275122771635" LOG_CI_START="-0.1502462495187962" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05385174914553994" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" P_CHI2="0.3378428233304235" P_Q="0.06934135865852864" P_Z="0.2735370564669196" Q="3.298544679955631" RANDOM="YES" SCALE="6.4" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.01091719640405145" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.094953430133936">
<NAME>All-cause mortality (subgroup: low risk of selection bias, trial truncation and co-interventions)</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.49482346211055517" CI_END="1.8333511230819008" CI_START="0.8167040223226788" DF="1" EFFECT_SIZE="1.2236442442764108" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.2632456489303012" LOG_CI_START="-0.08793530547646386" LOG_EFFECT_SIZE="0.08765517172691861" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.48178357113563497" P_Z="0.32786737120849185" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.504705052495574" Z="0.9784185474047148">
<NAME>Low risk of selection bias, no truncation, no co-intervention</NAME>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" ORDER="45" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.52970485219225"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" ORDER="50" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.975000200303324"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.026342351006568" CI_END="1.0044119298375316" CI_START="0.6256185325320713" DF="4" EFFECT_SIZE="0.792703423483627" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.0019118623760510662" LOG_CI_START="-0.20369039476725784" LOG_EFFECT_SIZE="-0.10088926619560333" MODIFIED="2011-02-16 20:24:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="0.5534268647208596" P_Z="0.05441562989006597" STUDIES="5" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="73.49529494750443" Z="1.923513203770216">
<NAME>Low risk of selection bias, truncation and/or with co-intervention</NAME>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" ORDER="54" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="25.749360455809807"/>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" ORDER="57" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.052256928074815"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" ORDER="56" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.6206689455046694"/>
<IV_DATA CI_END="1.3415374031044" CI_START="0.24219398765689884" EFFECT_SIZE="0.5700107834495196" ESTIMABLE="YES" ESTIMATE="-0.5621" LOG_CI_END="0.12760278564410968" LOG_CI_START="-0.6158366421997454" LOG_EFFECT_SIZE="-0.24411692827781786" ORDER="55" SE="0.4367" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.360588448309916"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" ORDER="56" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.712420169805227"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="10.756823162323906" CI_END="1.053409751464669" CI_START="0.6441819660524422" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="0.8237642652830511" ESTIMABLE="YES" I2="34.92502484824973" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.022597334324950123" LOG_CI_START="-0.19099143746966452" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08419705157235716" MODIFIED="2010-07-27 11:10:21 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.14958376011710495" P_Q="0.6830933062660608" P_Z="0.12228769749488201" Q="0.16666482086766693" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.042036831782355615" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.5452421707351423">
<NAME>All-cause mortality (subgroup: median survival in control group))</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.761288833384629" CI_END="1.1893949389858025" CI_START="0.5462735714812701" DF="3" EFFECT_SIZE="0.8060614252161691" ESTIMABLE="YES" I2="61.34662599985051" ID="CMP-001.06.01" LOG_CI_END="0.0753260861935133" LOG_CI_START="-0.2625898099878699" LOG_EFFECT_SIZE="-0.09363186189717829" MODIFIED="2010-07-27 11:09:56 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.051211638557798644" P_Z="0.2774089809231629" STUDIES="4" TAU2="0.09497688828083803" TOTAL_1="0" TOTAL_2="0" WEIGHT="61.28828422826676" Z="1.0861582967697512">
<NAME>Control group median survival &lt; 12 months</NAME>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" MODIFIED="2010-07-27 11:09:15 +0200" MODIFIED_BY="[Empty name]" ORDER="52" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.45141027454566"/>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" MODIFIED="2010-07-27 11:09:34 +0200" MODIFIED_BY="[Empty name]" ORDER="53" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.556405860369313"/>
<IV_DATA CI_END="0.8082298251912816" CI_START="0.30934714805140706" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09246512731950418" LOG_CI_START="-0.5095538834947836" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2010-07-27 11:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.245" STUDY_ID="STD-Lo-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.42299373509457"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" MODIFIED="2010-07-27 11:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.857474358257221"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.6095177457280165" CI_END="1.2374811876427918" CI_START="0.6482101300807614" DF="3" EFFECT_SIZE="0.8956270661466352" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.0925386054520481" LOG_CI_START="-0.18828418619520185" LOG_EFFECT_SIZE="-0.04787279037157686" MODIFIED="2010-07-27 11:10:21 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4558234529657923" P_Z="0.5039784385264494" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="38.71171577173323" Z="0.6682430896534058">
<NAME>Control group median survival &gt;12 months</NAME>
<IV_DATA CI_END="2.3857158333567865" CI_START="0.24850328379160838" EFFECT_SIZE="0.7699728688614912" ESTIMABLE="YES" ESTIMATE="-0.2614" LOG_CI_END="0.3776187128654618" LOG_CI_START="-0.6046678680044819" LOG_EFFECT_SIZE="-0.11352457756951001" MODIFIED="2010-07-27 11:10:11 +0200" MODIFIED_BY="[Empty name]" ORDER="56" SE="0.577" STUDY_ID="STD-Akamatsu-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.197979812425186"/>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" MODIFIED="2010-07-27 11:10:11 +0200" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.48058905579145"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" MODIFIED="2010-07-27 11:10:11 +0200" MODIFIED_BY="[Empty name]" ORDER="58" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.070897535983997"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" MODIFIED="2010-07-27 11:10:11 +0200" MODIFIED_BY="[Empty name]" ORDER="59" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.962249367532598"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.437042802375068" CI_END="1.0152940644662927" CI_START="0.6388775905978772" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.8053872519816481" ESTIMABLE="YES" I2="30.05184873192322" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.00659184725271662" LOG_CI_START="-0.19458234500351262" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09399524887539805" MODIFIED="2010-12-08 10:08:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.17814383185094695" P_Q="0.38685646405478624" P_Z="0.06702292941664878" Q="0.7487999756724395" RANDOM="YES" SCALE="5.32" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0361146355603602" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="1.8315202407177025">
<NAME>All-cause mortality (subgroup: trial truncation)</NAME>
<GROUP_LABEL_1>TACE or TAE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="8.497883407266686" CI_END="1.284494781619001" CI_START="0.614333373014776" DF="4" EFFECT_SIZE="0.8883175174518844" ESTIMABLE="YES" I2="52.929455391450404" ID="CMP-001.07.01" LOG_CI_END="0.10873234424372281" LOG_CI_START="-0.21159589144834062" LOG_EFFECT_SIZE="-0.05143177360230894" MODIFIED="2010-02-22 10:55:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07495153968411838" P_Z="0.529098957545486" STUDIES="5" TAU2="0.08853820079807508" TOTAL_1="0" TOTAL_2="0" WEIGHT="59.59547506649851" Z="0.6293820693249674">
<NAME>Non-truncated trials</NAME>
<IV_DATA CI_END="2.3857158333567865" CI_START="0.24850328379160838" EFFECT_SIZE="0.7699728688614912" ESTIMABLE="YES" ESTIMATE="-0.2614" LOG_CI_END="0.3776187128654618" LOG_CI_START="-0.6046678680044819" LOG_EFFECT_SIZE="-0.11352457756951001" MODIFIED="2010-02-17 11:09:34 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="55" SE="0.577" STUDY_ID="STD-Akamatsu-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.7839206151712834"/>
<IV_DATA CI_END="1.8196837109759159" CI_START="0.6613562019721911" EFFECT_SIZE="1.0970228383592084" ESTIMABLE="YES" ESTIMATE="0.0926" LOG_CI_END="0.25999590748231693" LOG_CI_START="-0.17956456943383467" LOG_EFFECT_SIZE="0.0402156690242411" MODIFIED="2010-02-17 11:09:34 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="24" SE="0.2582" STUDY_ID="STD-Bruix-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.586362506826699"/>
<IV_DATA CI_END="1.3687595582454284" CI_START="0.6318489618878248" EFFECT_SIZE="0.9299727447357862" ESTIMABLE="YES" ESTIMATE="-0.0726" LOG_CI_END="0.13632716493579344" LOG_CI_START="-0.19938672370814567" LOG_EFFECT_SIZE="-0.03152977938617608" ORDER="22" SE="0.1972" STUDY_ID="STD-Doffo_x00eb_l-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.61847639109979"/>
<IV_DATA CI_END="0.8082298251912816" CI_START="0.30934714805140706" EFFECT_SIZE="0.5000235908364827" ESTIMABLE="YES" ESTIMATE="-0.6931" LOG_CI_END="-0.09246512731950418" LOG_CI_START="-0.5095538834947836" LOG_EFFECT_SIZE="-0.30100950540714383" MODIFIED="2010-02-17 11:09:36 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="19" SE="0.245" STUDY_ID="STD-Lo-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.525037590951454"/>
<IV_DATA CI_END="2.906261788772815" CI_START="0.7575485534437884" EFFECT_SIZE="1.483790555979449" ESTIMABLE="YES" ESTIMATE="0.3946" LOG_CI_END="0.4633347318817188" LOG_CI_START="-0.12058952676367247" LOG_EFFECT_SIZE="0.17137260255902315" ORDER="21" SE="0.343" STUDY_ID="STD-Pelletier-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.081677962449275"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.9767979598506102" CI_END="0.9716813629953005" CI_START="0.5338753553648173" DF="3" EFFECT_SIZE="0.720247688625577" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.012476127028235473" LOG_CI_START="-0.27256012648447725" LOG_EFFECT_SIZE="-0.1425181267563564" MODIFIED="2009-12-17 09:26:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5772363442874224" P_Z="0.03171364539824051" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="40.404524933501506" Z="2.1480013854798408">
<NAME>Truncated trials</NAME>
<IV_DATA CI_END="1.1150282106680278" CI_START="0.45208742231985194" EFFECT_SIZE="0.7099931193855511" ESTIMABLE="YES" ESTIMATE="-0.3425" LOG_CI_END="0.047285855350517596" LOG_CI_START="-0.3447775754542451" LOG_EFFECT_SIZE="-0.1487458600518638" ORDER="17" SE="0.2303" STUDY_ID="STD-GETCH-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.66336656246321"/>
<IV_DATA CI_END="1.1717978732617627" CI_START="0.18852225541634016" EFFECT_SIZE="0.47001061473053796" ESTIMABLE="YES" ESTIMATE="-0.755" LOG_CI_END="0.06885270545548923" LOG_CI_START="-0.7246373731293995" LOG_EFFECT_SIZE="-0.32789233383695515" ORDER="15" SE="0.4661" STUDY_ID="STD-Llovet-_x005b_TACE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.511567040696521"/>
<IV_DATA CI_END="1.3415374031044" CI_START="0.24219398765689884" EFFECT_SIZE="0.5700107834495196" ESTIMABLE="YES" ESTIMATE="-0.5621" LOG_CI_END="0.12760278564410968" LOG_CI_START="-0.6158366421997454" LOG_EFFECT_SIZE="-0.24411692827781786" MODIFIED="2008-12-29 18:00:34 +0100" MODIFIED_BY="Roberto S Oliveri" ORDER="16" SE="0.4367" STUDY_ID="STD-Llovet-_x005b_TAE_x005d_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.1565224775062015"/>
<IV_DATA CI_END="1.549224407576051" CI_START="0.5463177987937994" EFFECT_SIZE="0.9199830803795124" ESTIMABLE="YES" ESTIMATE="-0.0834" LOG_CI_END="0.19011433055009896" LOG_CI_START="-0.2625546501315615" LOG_EFFECT_SIZE="-0.036220159790731184" MODIFIED="2009-12-17 09:26:39 +0100" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.2659" STUDY_ID="STD-Pelletier-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.073068852835577"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-06-08 14:55:55 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-10-08 15:18:25 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart illustrating search strategy and the different phases of the systematic review. Databases were searched from dates of inception to July 2010.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-07 14:24:13 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAo0AAAEACAMAAADhtbzkAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-11-07 14:24:13 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVIAAAMKCAIAAABY9VsLAAAl1klEQVR42u3dsW4Uyff28ZFICBw4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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-02-16 20:24:28 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:NO;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 TACE or TAE versus control, outcome: 1.1 All-cause mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="TSA, 10% RRR.BMP.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-02-16 20:48:32 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of the cumulative meta-analysis assessing TAE or TACE versus placebo or no intervention on survival in patients with non-resectable hepatocellular carcinoma. The required information size is based on an event proportion of 80% in the control group, a relative risk reduction of 10%, an alpha of 5%, a beta of 20%, and diversity of 13% and equals 1028 patients. The cumulative Z-curve (blue)<BR/>does not cross the trial sequential monitoring boundaries (red) and only 645 patients have been accrued so far, corresponding to 62.8% of the required information size.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApoAAAISCAIAAADjjfgdAABnz0lEQVR42uydB1gVZ9q/4ybfl+1f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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 6.jpg" FILE_TYPE="JPG" ID="FIG-06" MODIFIED="2012-06-08 14:55:55 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Meta-analysis on overall survival including only three TACE trials as suggested by SIR</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-06-08 15:27:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2012-06-08 15:27:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2012-05-16 10:57:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<I>Cochrane Review Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma (Review) 2011, Issue 3</I>
</TITLE>
<DATE_SUBMITTED>
<DATE DAY="2" MONTH="5" YEAR="2012"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-05-16 10:58:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Dear Colleagues:</P>
<P>The Society of Interventional Radiology (SIR) is a professional medical organization comprised of more than 4,700 medical practitioners in the United States and around the globe, many of whom perform transcatheter arterial chemoembolization (TACE) for treating hepatic malignancies. Several key content experts within our Society have critically reviewed the publication entitled <I>Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma (Review)</I> that was published on behalf of the Cochrane Hepato-Biliary Group in 2011. The conclusion of that Review stated that there was no firm evidence to support or refute TACE or transarterial embolization (TAE) for patients with unresectable HCC. </P>
<P>There are several questions that arose during our review of the document that we would appreciate clarification by the Cochrane Review group. We have concerns regarding the inclusion of several studies into the review, and it is our belief that if these studies were excluded from the meta-analysis the conclusion would in all likelihood support the use of chemoembolization (TACE) for patients with unresectable HCC. </P>
<P>Transcatheter arterial chemoembolization (TACE) and transarterial embolization (TAE) are not equivalent. TACE, as it is currently practiced, involves the administration of at least one cytotoxic chemotherapeutic agent delivered with solid embolic particles, with or without ethiodized oil. The embolization component of TACE is a technique used to reduce arterial inflow, while concomitantly increasing the contact time of the drug and the target tissue in an environment of tissue hypoxia/ischemia. This is in contrast to the goal of bland embolization (TAE), where particles without chemotherapy are delivered to the tissue with the sole intent of ischemia/infarction. </P>
<P>It is because of these differences that we believe TACE and TAE should not be combined into a single investigational group and that the review be limited to TACE alone. Using this methodology, three studies that were included in the initial review [Bruix 1998, Akamatsu 2004 and Llovet (TAE) 2002] should be excluded or analyzed separately. </P>
<P>A second concern raised by our group regards changes in techniques used over the very long time frame during which articles were evaluated for the Cochrane Review. Like any procedure or technique, TACE and the tools (catheters and guidewires) used to navigate the arterial anatomy and deliver the therapeutic regimen have evolved over the past three decades. Early techniques and randomized studies were carried out using less targeted delivery of the therapeutic regimen from the proper hepatic artery. The current standard of practice for TACE is to deliver the therapeutic regimen as close as possible to the target lesion in a lobar or segmental fashion to improve efficacy and safety of the intervention. Of the remaining six studies included in the meta-analysis, there are only three TACE studies that legitimately reflect the current standard of practice (Llovet 2002, Lo 2002 and Doffoel 2008) for chemoembolization described above. It is our contention that GETCH 1995, Pelletier 1990 and Pelletier 1998 should be excluded or at least weighted appropriately to take into account the less refined/evolved practice and the implications that may have on efficacy and survival. </P>
<P>We would appreciate your comments regarding our concerns described herein and would also appreciate your consideration to re-analyze the data based on the comments above. </P>
<P>SIR would be pleased to assist with identifying an interventional radiologist and a hepatologist with extensive experience with TACE for further discussion. If we can be of assistance in this effort, please do not hesitate to contact SIR Executive Director Susan E. Sedory Holzer, MA, CAE, at (703) 691-1805 or via e-mail at <A HREF="mailto:sholzer@SIRweb.org">sholzer@SIRweb.org</A>. </P>
<P>Thank you for your consideration.</P>
<P>Sincerely,</P>
<P>Marshall Hicks, MD, FSIR<BR/>President</P>
<P>and</P>
<P>Mike Wallace, MD, FSIR<BR/>Chair, IO Service Line</P>
<P>cc:  Susan E. Sedory Holzer, MA, CAE, SIR Executive Director.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-06-08 15:26:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Copenhagen, 5 June 2012.</P>
<P>Dear Colleagues,<BR/>
</P>
<P>We thank the Society of Interventional Radiology (SIR), represented by Drs. President Marshall Hicks and Chair Mike Wallace, for its interest in our Cochrane systematic review.<SUP>1</SUP> SIR states that several questions arose during its review process, which has led to concerns regarding the methodology and hence conclusions of our systematic review.<SUP>1</SUP> We address these concerns one by one.<BR/>
<BR/>First, SIR points out that transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) do not represent the same form of intervention. We agree that this may indeed be the case. For the same reason we conducted a subgroup analysis, stratified according to TACE or TAE, in our systematic review (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).<SUP>1</SUP> This meta-analysis demonstrated no statistical significant beneficial effect of TACE on overall survival (HR 0.79; 95% CI 0.58 to 1.06; P = 0.11). A similar subgroup analysis including only TACE trials with low risk of selection bias (analysis 1.3) reinforced this conclusion even further (HR 0.87; 95% CI 0.67 to 1.14; P = 0.33). Neither were there any significant effects of TAE.<SUP>1</SUP>
<BR/>
<BR/>Second, SIR stresses that TACE has evolved during the past decades criticising us for including trials performed back in the 1990s. Accordingly, SIR has the position that only three TACE trials (Llovet 2002; Lo 2002; Doffoël 2008)<SUP>2-4</SUP> legitimately represent the current standard of practice , which is why only these three trials should be included for quantitative analyses.<BR/>
<BR/>We would like to draw attention to the fact that SIR in its &#8220;Position Statement on Chemoembolization of Hepatic Malignancies&#8221;<SUP>5</SUP> recommends the use of TACE. In that statement, SIR cites data from the Llovet &amp; Bruix 2003 review.<SUP>6</SUP> Notably, this review also included the GETCH 1995 and Pelletier 1998 trials (besides the Lin et al. trial dating from 1988) in its meta-analyses.<SUP>7-9</SUP> Given SIR&#8217;s present concern of the outdated nature of certain trials, we find it surprising that SIR recommends the use of TACE partly based on data from the review by Llovet &amp; Bruix.<SUP>6 </SUP>
<BR/>
<BR/>For clarity, we have performed a meta-analysis including only the three trials as suggested by SIR (See <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>. Meta-analysis on overall survival including only three TACE trials as suggested by SIR).</P>
<P>As can be seen from the figure, the inclusion of the three most recent TACE trials as suggested by SIR does not change the conclusion of our Cochrane systematic review, namely that there is insufficient evidence to support or refute the use of TACE for unresectable HCC. Furthermore, as already pointed out in our Cochrane systematic review, the Llovet 2002 trial has some significant risks of bias which are known to affect intervention effect size including low number of events (deaths), trial truncation, and baseline imbalances. Likewise, Lo 2002 has high risk of selection bias, which is strongly associated with inflated intervention effect size.<BR/>
<BR/>SIR states in its letter that &#8220;it is our belief that if these studies were excluded from the meta-analysis the conclusion would in all likelihood support the use of chemoembolization (TACE) for unresectable HCC&#8221;. We have demonstrated in our reply above that this is unfortunately not the case.<BR/>
<BR/>We fully agree with the statement put forward in the aforementioned SIR position paper that &#8220;decisions regarding the merits of this therapy must be made based on the best available data&#8221;.<SUP>5</SUP> The Cochrane Hepato-Biliary Group and The Copenhagen Trial Unit, Centre for Clinical Intervention Research, will be pleased to assist SIR in its efforts to try to establish the true benefits and harms of TACE for patients with unresectable hepatocellular carcinoma by means of an adequately sized, low-risk of bias randomized clinical trial. Bending existing evidence towards current clinical practice does not seem a safe way forward.  </P>
<P>References </P>
<P>    1   Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. <I>Cochrane Database of Systematic Reviews</I> 2011, Issue 3. Art. No.: CD004787. DOI: 10.1002/14651858.CD004787.pub2.</P>
<P>    2   Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <I>Lancet</I> 2002;359:1734-9.</P>
<P>    3   Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. <I>Hepatology</I> 2002;35:1164-71.</P>
<P>    4   Doffoël M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S et al. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). <I>European Journal of Cancer</I> 2008;44:528-38.</P>
<P>    5   Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. <I>Journal of Vascular and Interventional Radiology</I> 2006;17:217-23.</P>
<P>    6   Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. <I>Hepatology</I> 2003;37:429-42.</P>
<P>    7   Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. <I>New English Journal of Medicine</I> 1995;332:1256-61.</P>
<P>    8   Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. <I>Gastroenterology</I> 1988;94:453-6.</P>
<P>    9   Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. <I>Journal of Hepatology</I> 1998;29:129-34.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-08 15:27:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Roberto S Oliveri, MD, PhD<BR/>Jørn Wetterslev, MD, PhD<BR/>and<BR/>Christian Gluud, MD, DMSc.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2011-02-16 20:24:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2011-02-16 20:24:08 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2008-09-29 15:27:57 +0200" MODIFIED_BY="Sarah Louise Klingenberg">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-16 20:24:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="4" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Name of database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search hits</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>September 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(((transcatheter OR transarterial) AND (emboli* OR chemoemboli*)) OR TAE OR TACE) AND ('hepatocellular carcinoma*' OR HCC* OR hepatoma*)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 4, 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Embolization, Therapeutic explode all trees<BR/>#2 ((transcatheter or transarterial) and (emboli* or chemoemboli*)) or TAE or TACE<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Carcinoma, Hepatocellular explode all trees<BR/>#5 hepatocellular carcinoma* OR HCC* OR hepatoma*<BR/>#6 (#4 OR #5)<BR/>#7 (#3 AND #6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>211</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1950 to September 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Embolization, Therapeutic/<BR/>2. (((transcatheter or transarterial) and (emboli* or chemoemboli*)) or TAE or TACE).mp. [mp=title, original title, abstract, name of substance word, subject heading word]<BR/>3. 1 or 2<BR/>4. exp Carcinoma, Hepatocellular/<BR/>5. (hepatocellular carcinoma* or HCC* or hepatoma*).mp. [mp=title, original title, abstract, name of substance word, subject heading word]<BR/>6. 4 or 5<BR/>7. 6 and 3<BR/>8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, original title, abstract, name of substance word, subject heading word]<BR/>9. 8 and 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>319</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to September 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Artificial Embolism/<BR/>2. (((transcatheter or transarterial) and (emboli* or chemoemboli*)) or TAE or TACE).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>3. 1 or 2<BR/>4. exp Liver Cell Carcinoma/<BR/>5. (hepatocellular carcinoma* or HCC* or hepatoma*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>6. 4 or 5<BR/>7. 6 and 3<BR/>8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>9. 8 and 7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>456</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (http://apps.isiknowledge.com)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to September 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 5 #4 AND #3<BR/># 4 TS=(random* or blind* or placebo* or meta-analysis)<BR/># 3 #2 AND #1<BR/># 2 TS=(hepatocellular carcinoma* OR HCC* OR hepatoma*)<BR/># 1 TS=(((transcatheter or transarterial) and (emboli* or chemoemboli*)) or TAE or TACE)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>622</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>From 1980 to September 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"carcinoma hepatocelular" AND ("embolizaciòn" OR "quimioembolizaciòn")</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>